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Abstract 
 
Microglia cells are the endogenous immune cells of the central nervous system. These 
cells play an important role in the defense of brain parenchyma against infectious diseases, 
trauma, neurodegeneration and brain tumors (such as glioma). It has been reported that glioma 
cells modulate microglia-mediated immune response in order to promote tumor proliferation. 
However, the mechanisms underlying such modulation are not yet completely clear. Several 
miRNAs, such as miR-21 and miR-155, have been reported has being overexpressed after 
immune activation of microglia and to be involved in the regulation of the immune response. In 
order to clarify how microglia-mediated immune response may be modulated by glioma cells, 
N9 microglia cells were incubated with glioma-conditioned medium, derived from GL261 mouse 
glioma cells, and evaluated the changes in the production of pro-inflammatory mediators. We 
observed an immune response, characterized by an increase in the mRNA levels of IL-1β and 
TNF-α (two pro-inflammatory cytokines) along with an increase of the expression of iNOS mRNA 
and nitric oxide production. Moreover, an increase in the expression miR-21 and miR-155 was 
observed. In order to unravel the role of miR-21 in the regulation of microglia immune response, 
N9 microglia cells were transduced with a lentiviral vector encoding a short-hairpin sequence 
against the mature form of miR-21 (anti-miR-21 lentivirus). This lentiviral vector also provides 
the cells with the ability to express GFP and, thus using this strategy, we generated N9 cells 
expressing GFP and low levels of miR-21 (N9 21). N9 cells transduced with a lentiviral vector 
encoding only GFP were used as control cells (N9 GFP). Following miR-21 silencing, we observed 
a decrease in the production of the pro-inflammatory cytokine IL-6 and a dramatic decrease in 
NO production, which suggests that this miRNA is required for a normal microglia-mediated 
immune response. A non-viral strategy was also employed to silence miR-21 in microglia, which 
involved the delivery of anti-miR-21 oligonucleotides to N9 microglia cells through DLS 
lipoplexes. Similar results were obtained with lentiviral- and DLS-mediated miR-21 silencing. 
Finally, to evaluate whether microglial activation would affect glioma cell proliferation, glioma 
cells were exposed to conditioned medium produced by N9 cells.  Surprisingly, silencing of miR-
21 in microglia enhanced glioma cell death through apoptosis when glioma cells were exposed 
to conditioned medium derived from N9 21 cells. Overall, our findings suggest that miR-21 plays 
an important role in microglia-mediated immune response, and that the silencing of this miRNA 
in microglia can contribute to glioma cell death through apoptosis. 
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Resumo 
 
As células da microglia constituem as células imunes endógenas do sistema nervoso 
central. Estas células têm um papel importante na defesa do parenquima cerebral contra 
infecções, traumas, neurodegeneração e tumores cerebrais (tal como o glioma). Vários estudos 
mostraram que as células de glioma conseguem modular a resposta imunitária mediada pela 
microglia de maneira a promover a proliferação tumoral. No entanto, os mecanismos 
subjacentes a esta modulação ainda não se encontram totalmente esclarecidos. Vários miRNAs, 
como o miR-21 e o miR-155, foram reportados estarem sobreexpressos após activação das 
células da microglia e desempenharem um papel importante na regulação da resposta 
imunitária. De forma a entender como é que a resposta imunitária mediada pela microglia pode 
ser modulada pelas células de glioma, células de microglia da linha celular N9 foram incubadas 
com meio condicionado proveniente de células GL261 de glioma de ratinho, tendo-se avaliado 
alterações em vários mediadores pró-inflamatórios. Observou-se uma resposta imunitária 
caracterizada por um aumento dos níveis de RNAm das citoquinas pro-inflamatórias IL-1β e TNF-
α, acompanhado de aumentos na expressão do RNAm da iNOS e na produção de óxido nítrico. 
Foram ainda observados aumentos na expressão de miR-21 e de miR-155. De maneira a tentar 
perceber em que medida o miR-21 estaria envolvido na regulação da resposta imunitária 
mediada pela microglia, procedeu-se à transdução das células N9 usando um vector lentiviral 
codificando um “short-hairpin” contra a sequência madura do miR-21). Este vector conferiu 
também às células a capacidade expressarem GFP, sendo assim gerada uma linha celular de 
microglia capaz de expressaando GFP e baixos níevis de miR-21 (N9 21). Como controlo, foi 
utilizado um vector lentiviral que codificando apenas GFP, gerando-se assim uma linha celular 
controlo que apenas expressava GFP (N9 GFP). Após o silenciamento do miR-21 na microglia, 
observou-se uma diminuição na produção da citocina pro-inflamatória IL-6 e de NO nestas 
células, o que sugere que o miR-21 é importante para uma resposta imunitária normal da 
microglia. Resultados semelhantes foram observados usando uma estratégia de transfecção não 
viral para entregar oligonucleótidos anti-niR-21 às células a fim de silenciar o miR-21 
(silenciamento por transfecção com lipoplexos DLS). Finalmente, de forma a avaliar em que 
medida a activação da microglia afecta a proliferação das células de glioma, este tipo de células 
tumorais foi incubado com meio condicionado das células da microglia. Surpreendentemente, a 
incubação das células de glioma com meio condicionado proveniente de células da microglia em 
que o miR-21 foi silenciado, resultou num aumento de morte celular por apoptose. No seu 
 
xiv 
 
conjunto, os nossos resultados sugerem que o miR-21 não só é importante para a resposta 
imunitária mediada pela microglia, como também o seu silenciamento na microglia parece 
potenciar a morte das células tumorais de glioma.  
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1.1 – Overview of Glioblastoma 
1.1.1 – Glioblastoma 
Primary brain tumors are neoplasms that develop from the various types of cells that 
constitute the brain. Approximately 50% of all primary brain tumors originate from the 
specialized neural cells, called glial cells, and therefore are called gliomas. Astrocytomas, gliomas 
that arise from astrocytes, are the most common type of primary brain tumors [1]. According to 
the World Health Organization (WHO), astrocytomas are classified into four grades depending 
on their growth rate and their ability to infiltrate to the nearby brain tissue [1, 2]. Grade I 
astrocytomas or Pilocytic Astrocytomas are slow growing and usually spreading astrocytomas. 
Grade II astrocytomas grow faster than the grade I astrocytomas, but are still considered slow 
growing tumors. Grade III astrocytomas, also called Anaplastic Astrocytomas, are infiltrating 
tumors that grow faster than lower grade astrocytomas. Finally, grade IV astrocytomas, or as 
they are more commonly known, glioblastomas, are the most malignat and fast growing 
astrocytomas [1, 2]. Glioblastoma (GBM), formerly known as glioblastoma multiforme[3], is the 
most common and malignant tumor within the central nervous system (CNS) [3-5], constituting 
between 15 to 20% of all intracranial tumors [5-8].  
1.1.2 – GBM classification and incidence rate 
GBMs can be classified either as primary (de novo) or as secondary (progressive), 
depending on the origin of the tumor. Primary GBMs arise without prior symptoms or signals of 
lower grade pathologies (Fig. 1). This type of GBM accounts for the majority of the cases, and is 
more common in old patients [9]. Secondary GBMs are quite rare and usually appear in patients 
under the age of 45 years old. They arise from lower grade astrocytomas, being estimated that 
approximately 70% of all grade II astrocytomas will evolve into higher grade gliomas within 5 to 
10 years after diagnosis[9]. GBM represents approximately 2% of all primary tumors with a 
worldwide incidence rate of 7 over 100.000 individuals per year. According to a recent survey, 
primary GBMs constitute the majority of GBMs (95%) compared with the secondary forms[10].  
Despite intense investigation on this pathology, over the past few decades the majority 
of patients diagnosed with GBM died within less than one year after diagnosis [10]. Standard 
treatment consists of surgical removal of the tumor, followed by chemotherapy and 
radiotherapy. Survival rate varies depending on the age of patients, being nearly 20% for 
patients below 30 years old, and nearly 5% for patients above 30 years old[11]. 
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1.1.3 – Main molecular characteristics of GBM 
 GBMs along with the high grade gliomas are diffuse tumors with a high ability to spread 
to the nearby brain tissue [9]. These tumors are characterized by uncontrolled proliferation, 
robust angiogenesis, intense resistance to apoptosis and genetic instability such as loss of 
heterozygosity [9, 12]. Among other genetic mutations, those associated with the cell cycle 
deregulation, such as the mutation of Retinoblastoma (RB) protein or p53, are of particular 
importance. RB 1, a gene located in chromosome 13q14 that encodes the RB protein has been 
shown to be mutated in at least 25% of high grade astrocytomas [13]. The RB protein, when 
hypophosporilated, binds and blocks the action of the E2F transcription factors family, thus 
promoting cell cycle arrest [9]. On the other hand, p53 is a well-known tumor suppressor that 
prevents the propagation of cells with unstable genomes, mainly by arresting the cell cycle in the 
G1 phase or leading the cell to a program of apoptosis[9, 14].  
 GBMs are very heterogeneous in cytologic composition, presenting more than one type 
of cells within the majority of the tumors [3, 15]. Cells of an individual glioma may differ in their 
morphology, genetics, and biological behavior. This heterogeneity occurs not only within an 
individual glioma and but also among different gliomas, and it is of particular importance in 
terms of tumor grading and assessment of therapeutic response and resistance[3]. Necrosis is 
often present and is associated with higher death rates [15]. There are several 
immunohistochemical markers important for a correct diagnosis of GBM, the glial fibrillary acidic 
protein (GFAP) and the oligodendrocyte transcription factor 2 (OLIG2) being the most useful and 
specific markers for clinical classification of gliomas [9]. GFAP is universally expressed in 
astrocytic and ependymal tumors but rarely in oligodendroglial tumors. OLIG2 is an 
oligodendroglial marker, which is CNS specific and universally and abundantly expressed in all 
diffuse gliomas[9]. Several immunohistochemical stem cell markers, such as CD133, Nestin or 
Musashi have been demonstrated as being present not only in high grade gliomas, but also in 
lower grade ones, suggesting the presence of cancer stem cells within the tumor tissue, which 
corroborates with the recurrence of the disease after conventional treatment[9, 16]. 
1.1.4 – GBM therapy: Conventional treatment and novel therapeutic approaches  
1.1.4.1 - Conventional treatment 
The standard treatment for GBM begins, when possible,  with the surgical resection of 
the maximal tumor possible followed by the combined action of radiotherapy and 
chemotherapy [8]. The surgical removal of the complete tumor is impossible in most cases, due 
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to the fact that glioma tumors grow diffusely and infiltrate frequently into the nearby brain 
tissue. Nowadays, the 5-aminolevulinic acid (a fluorescent label) is being tested as a tumor 
contrast agent, in order to help the surgeons to achieve a more accurate image of the tumor and 
thus remove it more efficiently [8, 17]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Currently, the treatment of GBM can be divided into two situations: initial treatment of 
disease and treatment of recurrent disease. New techniques and new therapeutic agents are 
always tested first in cases where the disease is recurrent, and their implementation in the initial 
treatment of the disease is dependent on the results obtained in those first tests [17]. 
1.1.4.2 – Conventional and new chemotherapeutic agents    
The major drugs used for the treatment of GBM are alkylating agents such as 
temozolamide (TMZ), bis-chloroethylnitrosourea (BCNU) and procarbazine [17-20]. However, 
many GBMs acquire resistance to these kinds of drugs through demethylation of the promoter 
of the gene encoding the O’-6-methylguanine-DNA methyltransferase (MGMT), an enzyme 
Fig. 1 – GBM. Primary (or de novo) GBMs arise directly from glioma precursor cells. In contrast, secondary GBMs 
develop from the progression of low-grade tumors through sequential accumulation of molecular changes [9]. 
EGFR: Epidermal growth factor receptor; LOH: Loss of heterozygosity; PDGF: Platelet-derived growth factor; PDGFR: 
Platelet-derived growth factor receptor; VEGF: Vascular endothelial growth factor; DCC: Deleted in colorectal 
cancer. Adapted from [20] 
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involved in DNA repair [8, 17, 21]. Implantation of biodegradable polymers impregnated with 
BCNU arose as a new strategy for treatment of GBM after surgery. It has been shown that when 
combined with fractionated radiotherapy and TMZ, this strategy improved overall survival of the 
patients several months [8]. Cytostatic drugs are also used in the treatment of GBM such as cis-
retinoic acid, thalidomide, tamoxifen or celecobix. These drugs alter the tumor biology 
preventing its growth and spread, but they do not kill tumor cells by themselves [19].  
As GBM biology is unraveled, understanding of their distorted signaling pathways 
increases and several molecules have been designed to target these pathways. Tyrosine kinase 
receptors (TKRs), such as the receptors for the epidermal growth factor (EGF), platelet derived 
growth factor (PDGF) or the vascular endothelial growth factor (VEGF), are important targets in 
GBM due to their role in tumor growth, spread and angiogenesis [12, 22, 23]. Several drugs that 
interfere with TKR pathways, either by inhibiting the receptors or other proteins of their 
pathways, have already been designed (see Fig. 2). Among others, drugs such as sunitinib (an 
inhibitor of the VEGF receptor) or erlotinib hydrochloride (an inhibitor of the EGF receptor) are 
already being used in the clinic [12]. 
1.1.4.3 – Immunotherapy 
 Immunization against tumors can be very similar to immunization against infections. In a 
passive immunotherapy approach, the patient is inoculated with in vitro activated immune cells, 
capable of targeting the tumor cells, thus sparing the activation of the patient’s own immune 
system. On the other hand, an active immunotherapy approach provides a boost to the native 
immune system of the patient [24]. 
Over the past few years, the interest in an immunotherapeutic approach for GBM rose 
significantly, particularly in the field of molecular targets that may turn the tumor more visible to 
the immune system (also known as immunotherapeutic agents)[25]. GBM genetic instability, 
although being the main cause of uncontrolled cell growth, may be an open window in what 
concerns to the appearance of tumor antigens passible of being recognized by immune T cells. 
Generally, tumor cells contain specific antigens that can be recognized by T cells [25]. However, 
tumor microenvironments are highly immunosuppressive, due to the presence of anti-
inflammatory stimuli, such as interleukin (IL)-4, IL-10, IL-13 transforming growth factor (TGF)-β 
or corticosteroids [25, 26], thus impairing, not only T cell function, but also the action of other 
cells (such as macrophages) responsible for innate immune responses [25, 26].  
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 GBMs, like other  tumors, are able to overcome host immune defenses through several 
mechanisms, particularly due to the partial immunologic privilege of the brain, which is a 
characteristic of note in this kind of tumor [25]. The brain is an immunologically privileged organ 
due to the presence of the blood brain barrier (BBB). Although activated T cells may cross the 
BBB and enter the brain in specific situations, the number of cells that remain in an activated 
state is limited [25]. This is mainly due to the brain environment which is mainly anti-
inflammatory and rich in TGB-β, a factor responsible for the downregulation of human leukocyte 
antigen (HLA) class II in antigen presenting cells (APCs), such as microglia, macrophages or 
dendritic cells (DCs), which leads to impaired T cell activation through APCs [25, 26]. In addition, 
studies have shown that infiltrating APCs, although expressing HLA class II, lack the expression of 
the costimulatory molecules CD80, CD86 and CD40, which are critical for T cell activation[25, 
27]. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 DCs are the most potent APCs and are commonly used for active specific 
immunotherapy. With DC based vaccines, tumor regression has been observed in a number of 
Fig. 2 - Growth factor pathways demonstrating the presence targets for new molecular agents, with examples of 
agents currently under study. EGFR - epidermal growth factor receptor; GDP - guanosine diphosphate; Grb2 - 
growth factor receptor-bound 2; GTP - guanosine triphosphate; HGF - hepatocyte growth factor; MAPK - mitogen-
activated protein kinase; MEK - MAPK kinase; mTOR - mammalian target of rapamycin; P - phosphate group; PDGFR 
- platelet-derived growth factor receptor; PDK - phosphatidylinositol-dependent kinase; PI3K - phosphoinositide-3 
kinase; PIP2 - phosphatidylinositol 4,5-bisphosphate; PIP3 - phosphatidylinositol 3,4,5-triphosphate; PTEN - 
phosphate and tensin homologue; and TSC - tuberous sclerosis complex. Adapted from [17]. 
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cancer patients, including GBM patients [28, 29]. The analysis of antigen specific T cells following 
DC-based therapy also shows a strong increase in cytotoxic T lymphocytes (CTL) in the blood and 
an overall increase in CTL infiltration in the tumor [25]. Various strategies have been employed 
in the past in order to load DCs, these including among others, acid-eluted membrane peptides 
[30], tumor lysates [31] and specific predicted T cell epitopes from known players in glioma 
biology, such as the mutated form of the EGF receptor, EGFRvIII [32]. 
1.1.4.4 – Gene Therapy 
 Gene therapy has its basis in the premise that DNA can be used as pharmaceutical agent, 
either by modifying an already existing cell gene or through the insertion of new genes into a 
cell. Gene delivery can be accomplished using a variety of vectors, such as viruses, polymers or 
liposomes [17]. In gliomas, viral vectors, such as retroviruses and adenoviruses, have been used 
to deliver suicide and proapoptotic genes, such as the Herpes simplex virus tyrosine kinase (HSV-
TK) that converts the prodrug ganciclovir (GCV) into an active drug  GCV-monophosphate, which 
may then be triphosphorylated and inserted into the DNA during replication. This strategy 
inhibits the action of the DNA polymerase, thus leading to chain termination and cell death [33]. 
Despite promising, these studies have been discontinued due to low transduction efficiency and 
other adverse symptoms in the patients [17, 33]. Liposomal vectors, for example, have been 
used to deliver therapeutic genes in the preclinical setting [17], such as shown in the work of 
Ramesh and colleagues where they describe cationic liposomes that efficiently deliver 
therapeutic tumor suppressor genes p53 and Bis (5'-adenosyl)-triphosphatase (FHIT) to lung 
cancer metastasis in mice [34]. 
 More recently, small RNA molecules, such as small interfering RNAs (siRNAs) or 
microRNAs (miRNAs), have emerged as promising active agents and targets. Both siRNAs and 
miRNAs may regulate gene expression at the RNA level by pairing perfectly or imperfectly with 
their target mRNAs, thus repressing their translation or signaling them to be degraded 
[35].These small molecules can be complexed with liposomal vectors (siRNAs) or inserted into 
viral genomic cassettes (miRNA) as a way to promote their delivery into the cell [36]. The 
combination of miRNA regulation with gene therapy strategies allows to target and potently 
modulate the expression of endogenous genes, either by downregulation of the gene mRNA or 
by the silencing of a specific miRNA aiming at downregulating a specific mRNA [36]. In this 
regard, recent study has shown the silencing of miR-21 (a miRNA known to be overexpressed in 
GBM [37, 38]) enhances the vulnerability of GBM cells to the TRK inhibitor sunitinib [39]. 
Carlos Custódia 
 
9 
 
1.2 – GBM interaction with the immune system 
1.2.1 – GBM antigens  
 T lymphocytes monitor the peptides presented at the cell surface by the major 
histocompatibility complex molecules, known as human leukocyte antigen (HLA) in humans [40]. 
As in other types of cancers, it has been proven that GBM cells express several peptides in their 
membrane and that can be recognized by the T lymphocytes as tumor antigens, thus triggering 
their activation. Moreover, it was shown that GBM patients exhibit circulating tumor-specific 
CD8+ cytotoxic T lymphocytes (CTLs) and that CTLs provide selective and effective immune 
surveillance of the brain, which suggests that GBM is an antigenic tumor [41, 42].  
The ideal glioma-associated antigen is one protein or peptide that is expressed only in 
GBM tissue but not in normal brain tissue. Several studies have already demonstrated the 
presence of such ideal antigens, such as the work performed by Liu et al., where it is described 
that primary GBM cells with high-level MAGE-1 or gp100 expression stimulated IFN-γ production 
by cognate antigen-specific CTL clones [43]. Other important glioma-associated antigens are the 
EGFRvIII, which results from a mutation of the EGF receptor that originates a glioma-specific 
mutant protein, or the squamous cell carcinoma antigen recognized by T-cells (SART)-3 protein. 
Both of these antigens are expressed in GBM, but not in normal brain [44, 45]. A detailed list of 
human glioma-associated antigens can be found in Table 1. 
1.2.2 – GBM microenvironment, tumor infiltrating cells and immune modulation 
Glioma tissue contains more than just cancer cells. A considerable amount of 
nontransformed cells are present within the tumor, the majority of those being immune cells 
responsible for innate immune responses as microglia (nearly one third of tumor mass), tumor-
associated macrophages (TAMs), and mast cells [26, 46-48]. GBM microenvironment is highly 
rich in growth factors and cytokines that play critical roles, not only in the autocrine stimulation 
of tumor cells, leading to an increase of protease expression and to an enhancement of cell 
migration, but also acting as suppressors of the immune system cells, preventing these cells 
from killing tumor cells [49]. Human GBMs cells secrete factors, such as prostaglandin E (PGE), 
IL-10, VEGF and TGF-β, which are capable of suppressing several immune functions [25, 49]. 
TGF-β has been shown to suppress the cytotoxic response of glioma-derived T cells against 
tumor targets, including autologous glioma cells. Glioma-derived IL-10 has also been shown to 
downregulate MHC Class II expression on monocytes and suppresses T cell proliferation [49].  
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Table 1 – Human glioma-associated antigens.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tumor infiltrating immune system cells have been shown to have a dual role. In a first 
instance, TAMs and microglia secrete anti-tumor cytokines and interact with T cells to destroy 
cancer cells. These cells assume a M1 phenotype characterized by high phagocytic ability, 
production of pro-inflammatory cytokines and antigen presentation, [26, 50]. In addition to 
secretion of chemotaxic molecules, such the macrophage colony stimulating factor (MCS-F), 
blood monocytes are attracted to the tumor microenvironment, where they are exposed to anti-
inflammatory stimuli released by tumor cells, undergoing differentiation to an alternatively 
activated type of macrophages, called M2 macrophages. This differentiation process is 
Adapted from [44]. 
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promoted by the downregulation of IFN-γ (produced by T cells). These M2 macrophages play a 
role in the control of the inflammatory response by secreting, along with other molecules, IL-10, 
which is a cytokine known for its anti-inflammatory properties. However, this phenotype has 
been shown to be beneficial to tumor development, since it downregulates M1-mediated 
responses and prevents tumor cell death (see Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Fig. 3 – Monocyte differential fates. Blood monocyte differentiate into M1 type in the presence of LPS/IFN-γ 
(classically activated macrophages). M1 macrophages produce high levels of pro-inflammatory cytokines and are 
characterized by cytotoxic activity against microorganisms and neoplastic cells. On the other hand, when monocytes 
differentiate in the presence of IL-4, IL-13, IL-10, or corticosteroids, they mature into M2 macrophages (alternatively 
activated), which secrete amongt others IL-10, which is an anti-inflammatory cytokine. M2 cells are active workers 
of the host, promoting scavenging of debris, angiogenesis, remodeling, and repair of wounded/damaged tissues. 
Within the tumor mass, they exert the same functions favoring tumor promotion. In addition, M2 macrophages 
control the inflammatory response by down-regulating M1-mediated functions and adaptive immunity. Adapted 
from [26].  
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1.3 – Overview of microglia 
1.3.1 – Microglia 
The specialized macrophages of the CNS are called microglia. Microglia is distinguished 
from neural and other glial cells (such as astrocytes and oligodendrocytes) based on its 
haematopoietic origin, morphology, gene expression pattern and cellular fuctions [51, 52]. The 
concept of microglia as a defined cellular element of the CNS was first introduced by Pio del Rio-
Hortega in 1932 [52]. Depending on the region of the CNS, microglia constitute 5 to 20% of total 
glial cells in rodents [53]. Unlike other populations of macrophages, on its resting state, microglia 
exhibit ramified extensions that emerge from cell body that communicate with the surrounding 
neurons and glial cells. On the other hand, upon infectious or traumatic stimuli, these cells adopt 
an amoeboid activated phenotype, and produce many pro-inflammatory mediators, such as 
cytokines, chemokines, reactive oxygen species (ROS) and nitric oxide, which contribute to the 
clearance of pathogen infections. However, prolonged or excessive microglial cell activation may 
result in pathological forms of inflammation that contribute to the progression of 
neurodegenerative and neoplastic diseases [53, 54]. The role of microglia in health and disease 
has enhanced the efforts to understand more clearly how their activity is  regulated and which 
mechanisms are involved in such regulation [53]. 
1.3.2 – Microglia origin and microglial markers 
The origin of microglia has been a matter of debate for a long time. It has been proposed 
that microglia has the same progenitor cells as astroglia in the neuroectoderm [55]. Today, 
however, it is of general consensus that these cells arise from mesodermal progenitor cells 
(more specifically myeloid cells) that migrate to the CNS before their complete maturation. 
Despite this general consensus, microglia origin is still a matter of debate, and the major 
questions in this field are now focused on the way and type of progenitor cells that migrate to 
the CNS, and also the time points at which such migration occurs. In a recent review by 
Kettenmann et al. it is suggested that in rodents, microglia originate from monocytic like 
precursor cells, produced in the bone marrow, which migrate towards the brain until postnatal 
day 10 [51]. However, in their recent study, Guilhoux and colleagues demonstrated, using fate 
mapping in mice, that microglia arise from yolk sac progenitor cells around embryonic days (E) 7 
and 7.5, enter the embryo around E8 and finally colonize the CNS near E10 (Fig.4) [56, 57]. 
Moreover, in this study, microglia is identified as an ontogenically distinct population in the 
mononuclear phagocyte system [56]. 
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Despite the discussion on microglia origin, it is of common consensus that these cells 
belong to the haematopoietic lineage, sharing the same precursor cells as macrophages or 
monocytes. Along with DCs, microglia, macrophages and monocytes are classified as 
mononuclear phagocytes (Fig.5) [58].  
 
 
 
 
 
 
 
 
 
 
 
 
Microglia shares several immunohistochemical markers with macrophages, such as 
CD11b, CD11c, CD68 and EGF-like module-containing mucin-like hormone receptor-like 1 (EMR1; 
also known as F4/80 in mice) [53, 59]. However, it is possible to distinguish activated microglia 
from macrophages based for example on peroxidase activity (present in macrophages but 
Fig. 4 – Embryological origins of microglia as proposed by Guilhoux et al.. Microglial progenitors arise in the yolk sac 
between E7–7.5, enter the embryo at E8 and surround the neuroepithelium by E9.5, between the surface ectoderm 
and brain rudiment. At E10.5, the earliest microglia are found in the neuroepithelium. Adapted from [57]. 
Fig. 5 – How microglia is related to haematopoietic and CNS cells. Microglia are the only haematopoietic cells found 
in the parenchyma of the CNS. Note that the derivation of the perivascular, choroid plexus and meningeal 
macrophages from the monocyte–dendritic-cell progenitor is speculative and the blood cell from which they originate 
is unknown. Adapted from [58]. 
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absent in microglia), and on the expression of CD45 or Laminin-5 (LN-5) wich is higher in 
macrophages, but low to none in microglia [59]. Table 2 summarizes several consensual markers 
for distinguishing between microglia and macrophages. It is of general agreement that microglia 
profile of characterization is: CD68+, CD45 low, CD11b+, CD11c high, MHC class II+, CD14– [59]. 
 
 
 
 
 
 
 
 
 
1.3.3 – Microglia activation and microglia-mediated immune response 
1.3.3.1 – Classical microglia activation 
 Microglial activation is a quick process that can be triggered by a variety of stimuli, such 
as infection or tissue injury. During the process of classical microglia activation, several changes 
concerning protein expression and cell morphology occur on microglia phenotype [53, 60]. 
Microglia expresses pattern-recognition receptors (PRRs), including toll like receptors (TLRs), RIG
‑I-like receptors (RLRs), NOD-like receptors (NLRs) and C‑type lectin receptors, thus acting as 
the primary sensor for pathogen-associated molecular patterns (PAMPs) in the CNS [53]. 
Activated microglia upregulates MHC class II expression, required for activation of naive T cells, 
and produces numerous pro-inflammatory cytokines, including cytokines that induce the 
differentiation of effector T cells (Fig.6)[53]. Microglia expresses all TLRs, which recognize a 
variety of different stimuli [61]. As an example, TLR4 along with CD14 recognizes 
lipopolysaccharide (LPS), a component of the cell walls of Gram-negative bacteria [53, 62]. 
Microglial activation can be acute or chronic, which has been suggested to depend not only on 
the duration of an external cue, but also on the specific factor (stress, infection, inflammation, 
signals from damaged neurons) responsible for the activation process [63]. 
 
Table 2 – Selection of several markers used to distinguish microglia from macrophages. Adapted from 
[59] 
Adapted from [59] 
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Morphological changes also occur when microglia is activated. During activation, 
microglia changes from a ramified to a hyperramified phenotype and subsequently adopts an 
amoeboid morphology, a process which has been suggested to help microglia invade lesion sites 
(Fig.7) [60]. 
 
 
 
 
 
 
Fig. 6 - Classically activated microglia participates in both innate and adaptive immune responses. Microglia express 
pattern recognition receptors (PRRs) that recognize various pathogen-associated molecular patterns (PAMPS) found 
on bacteria and viruses. Following the recognition of PAMPs by microglia, PRR-mediated signalling induces the 
production of antimicrobial peptides (such as cathelicidin-related antimicrobial peptide (CRAMP)), cytokines (such as 
tumour necrosis factor (TNF) and interleukin-1β (IL-1β)), chemokines (such as CC-chemokine ligand 2 (CCL2)), reactive 
oxygen species (ROS) and nitric oxide (NO). These molecules have key roles in innate immunity and are characteristic 
features of the classical M1-like microglial cell phenotype. Activated microglia also upregulates the expression of MHC 
class II molecules which allow the presentation of antigens to T cells through the T cell receptor (TCR). In addition, 
activated microglia produces pro-inflammatory cytokines (such as IL-12) to skew CD4
+ 
T cells into T helper 1 (TH1) 
cells, or IL-23, IL-6, IL-1β and transforming growth factor-β (TGFβ) to differentiate and activate TH 17 cells. Therefore, 
classically activated microglia contributes to both innate and adaptive immunity. Adapted from [53]. 
Fig. 7 – Standard profile of microglia morphology during the activation process. Adapted from [54]. 
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1.3.3.2 – Alternative microglia activation 
 As previously discussed in subsection 1.2.2, it is thought that, like macrophages, 
microglia also may be activated into two different types of phenotypes, the classical M1 and the 
alternative M2. Like macrophages, M2 activation of microglia is thought to be induced by IL-4 
and IL-10, although there is no clear evidence has been provided [53]. As also previously 
mentioned, glioma cells are known to produce several immune suppressive factors, such as the 
anti-inflammatory cytokines IL-4, IL-6 or TGF-β, which are described as driving microglia 
differentiation into an M2 phenotype (Fig.8). Microglia-like cells are often observed around and 
within gliomas, however, it is not clear whether these cells are entirely derived from the resident 
microglial cell population or are macrophages that migrate from the blood stream. Several lines 
of evidence suggest that glioma-associated microglia might be different from classically 
activated microglia and more related to alternatively activated macrophages.  
 
 
 
 
 
 
 
 
The role of microglia in tumor development has also been a matter of intense debate. In 
two recent studies, performed by Markovic and colleagues, it was shown that microglia 
promotes glioma progression by expressing matrix-degrading metalloproteinases (MMPs) such 
as MMP-2 and MT1-MMP. These MMPs allow cancer cells to easily migrate and invade healthy 
tissue [64, 65]. In another study, Zhai et al. showed that when microglia first interacts with 
glioma cancer cells, it becomes activated, although at later time points phagocytosis is 
significantly decreased and the growth of glioma cells is unaffected. This suggests the presence 
of immunosuppressive molecules within gliomas [66]. Zhai and colleagues also performed an in 
vivo assay where they ablated the presence of microglia in C57/BL6 mice brains and verified that 
tumor growth was significantly decreased. This may be explained taking into consideration that 
Fig. 8 - Glioma cells secrete factors that induce an M2-like microglial cell phenotype. These factors include 
transforming growth factor-β (TGFβ), interleukin-4 (IL-4), IL-6 and IL-10.Adapted from [53]. 
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microglia and TAMs are a great source of immunosuppressive cytokines within the tumors and 
produce MMPs that degrade the cellular matrix, aiding the tumor to invade the surrounding 
tissues [64-66]. Another two studies performed by Hussain and colleagues showed that 
microglia isolated from gliomas expresses TLRs and is capable of innate immune responses such 
as phagocytosis and cytotoxicity, however its capacity to be stimulated via TLRs, secrete 
cytokines, upregulate costimulatory molecules (CD86, CD80 and CD40), and in turn activate 
antitumor effector T cells is not sufficient to initiate immune responses [27, 67]. 
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1.4 – MicroRNA biogenesis and function 
1.4.1 – Overview of microRNA biology and biogenesis 
MicroRNAs (miRNAs) are short noncoding RNAs, 18 to 25 nucleotides long which are 
expressed endogenously in all eukaryotes.  Their history begins in 1993 when Lee, Feinbaum and 
Ambros discovered that C. elegans gene lin-4 did not encode a protein, but two small RNA 
transcripts instead [68]. These two RNA transcripts were proved to regulate larval development 
by repressing lin-14 (a gene that encodes a nuclear protein) translation [68]. They proposed that 
lin-14 regulation was in part due to sequence complementarity between lin-4 and unique 
repeats within the 3' UTR of the lin-14 mRNA. Seven years later, Reinhart et al. described 
another miRNA in C. elegans, miRNA let-7. This miRNA was similar to lin-4 and also regulated 
developmental timing in C. elegans [69]. At present, we know that these short RNAs are highly 
conserved gene expression regulators that act by binding mainly to the 3’UTR region of their 
target mRNAs [70]. 
1.4.1.1 – Canonical pathway for miRNA biogenesis 
MiRNAs are transcribed from the genome by an RNA polymerase II, which originates 
larger RNA molecules called primary transcripts (pri-miRs). Many of these pri-miRs are 
polyadenylated and capped after transcription [71] and within these larger RNAs, the mature 
microRNA sequences form imperfect hair-pin-loop structures. Some pri-miRs transcripts contain 
clusters of several miRNAs that are processed to their mature forms from a single primary 
transcript, while others contain only a single microRNA [72]. After being transcribed, pri-miRs 
are processed by Drosha (an RNase III enzyme present in the nucleus) and by the dsRNA-binding 
protein DGCR8 (also known as Pasha in invertebrates) originating an RNA molecule 
approximately 70 nucleotide long called pre-miR (Fig.9). The pre-miRs are then transported to 
the cytoplasm, by exportin 5, where they are further processed by Dicer, who excises a double 
stranded RNA with 20-22 nucleotides from the hairpin structure, which is referred as 
miRNA:miRNA* duplex [70]. This double stranded RNA becomes associated with Argonaute 
proteins and forms the RISC (RNA induced silencing) complex. Then, the miRNA* (sense strand) 
is degraded and the complex is directed, by base-pair complementarity, to the target mRNAs of 
the mature miRNA [70, 71].  
MiRNAs interact partially with the 3’ UTR region of the target mRNA, which permits 
them to have more than one target mRNA, allowing the miRNA to regulate simultaneously ga 
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large number of genes. This has already been demonstrated experimentally by Grimsom and 
colleagues [73]. In addition, many genes have predicted target sites for several different 
microRNAs in their 3’ UTRs, as well as multiple target sites for the same miRNA.   
1.4.1.2 – Non-canonical pathway for miRNA biogenesis 
In 2007, an alternative (non-conventional) pathway, whicht produces miRNA precursors 
via splicing, was discovered and characterized in invertebrates [74]. The miRNAs originated 
through this pathway are called mirtrons and are defined by Sibley and colleagues as small RNA 
molecules with unpaired flanking sequences, immediately adjacent to the splice junctions that 
are clustered at the outer edge of short introns [75]. Mirtrons are splicing-produced short-
hairpin introns that mimic the structural hallmarks of pre-miRNAs and therefore enter the 
canonical miRNA-processing pathway at a later stage [76]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9 – Mechanisms of miRNA biogenesis and miRNA-containing ribonucleoprotein complex (miRNP) assembly: a - 
The canonical pathway, involving the production of precursor miRNAs (pre-miRNAs) by Drosha-mediated cleavage of 
primary miRNA transcripts (pri-miRNA) and the recently discovered non-canonical pathway, involving the production 
of pre-miRNAs by splicing-mediated cleavage of short-hairpin introns (mirtrons); b - Following their processing, 
miRNAs are assembled into ribonucleoprotein (RNP) complexes called micro-RNPs (miRNPs) or miRNA-induced 
silencing complexes (miRISCs). The assembly is a dynamic process, usually coupled with pre-miRNA processing by 
Dicer, but its details are not well understood. The key components of miRNPs are proteins of the Argonaute (AGO) 
family. In mammals, four AGO proteins (AGO1 to AGO4) function in the miRNA repression pathway but only AGO2 
functions in RNAi. DGCR8: DiGeorge syndrome criticical region gene 8 protein; TRBP: RNA-binding protein TAR; Ago1-
4: argonaute protein 1-4; CCR4-NOT: C-C chemokine receptor type 4-NOT. Adapted from [76]. 
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1.4.1.3 – MiRNA silencing mechanism 
 In the miRNA 5’ terminal exists a sub-region of 6 to 8 nucleotides, called seed region, 
which is responsible for the specific binding of the miRNA to the mRNA (Fig.10). The seed region 
binds to the target mRNA at its 3’ UTR region. The binding specificity and efficiency of the 
miRNA:mRNA duplex is modulated by the number and position of the complementary 
nucleotides. There are always six nucleotides of the miRNA that bind to the 3’ UTR of the mRNA, 
however, if adjacent nucleotides can also bind this will increase the specificity and the efficiency 
of the recognition [73]. The binding of the miRNA to the mRNA leads to the inhibition of mRNA 
translation or to the deadenylation and degradation of the mRNA, severely affecting mRNA 
stability. Therefore, the protein encoded by mRNA undergoes downregulation and its levels in 
the cytoplasm decrease [70]. 
 
 
 
 
 
 
1.4.2 – The biological roles of miRNAs in glioma 
 In mammals, miRNAs play a role in the majority of basic cellular processes - such as 
embryonic development, cell differentiation, metabolism, cell proliferation and cell death - in a 
wide range of invertebrate and vertebrate organisms (including humans) [77-80]. Widespread 
influence of miRNAs is also observed in (the regulation of) different physiological responses, 
including cardiovascular development [81], stem cell differentiation [82] or innate and adaptive 
immunity [83]. It has also been described that miRNAs have characteristic patterns of expression 
during brain development and neuronal differentiation [84, 85]. It is thought that at least one-
third of all protein-encoding genes in the human genome may be regulated by miRNAs [86]. 
Therefore, deregulation of physiologic miRNA activity plays an important role in the appearance 
of several human diseases, including cardiovascular, neurological disorders and cancer [86-88].  
 
 
Fig. 10 – Canonical miRNA complementary sites. Adapted from [73]. 
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1.4.2.1 – MiRNAs involved in gliomagenesis 
Some features of carcinogenesis, such as apoptosis, cell proliferation, invasion and 
migration have been related to miRNA deregulation and several miRNA, such as miR-7, miR-21 
or miR-128 have already been described as being deregulated in glioma [37, 89, 90].  
 MiR-21 has emerged as one of the most consistently highly expressed miRNAs in cancer 
[72, 89]. In the study of Papagiannakopoulos et al. several tumor supressor protein pathways 
were identified as targets of this miRNA, such as the TGF-β or the AKT pathways. Direct targets 
of miR-21 include p53 analogue p63, TGF-β receptors and DAXX (Fig.11), this later being both a 
mediator of the TGF-β pathway and p53 stabilizer, and involved in the crosstalk of these two 
apoptotic pathways [37]. Therefore, by targeting of these genes, miR-21 disrupts the normal 
function of these anti-apoptotic factors, contributing to oncogenesis. Two other mir-21 targets 
are tissue inhibitor metalloproteinase (TIMP) 3 and reversion-inducing-cysteine-rich protein with 
kazal motifs (RECK). These proteins are inhibitors of matrix metalloproteinases (MMPs) [91].  
In their study in 2005, Chan and colleagues showed that miR-21 is highly expressed in 
GBM. These authors observed that miR-21 knockdown in GBM cell lines triggered caspase 
activation and associated apoptotic cell death, suggesting an anti-apoptotic function for miR-21. 
In the same study, it was shown that miR-21 targets programed cell death 4 (PDCD4), which is a 
tumor suppressor. This protein is thought to be an inhibitor of cell proliferation via p21, which 
promotes growth arrest [38]. Taken together, these studies suggest that miR-21 is clearly an 
oncomir that negatively regulates several specific molecules with tumor suppressor functions. 
This miRNA may play a role in the pathogenesis of several different kinds of cancers, and 
particularly in GBM. Therefore, miR-21 downregulation can be considered a promising 
therapeutic approach for human GBM in the future. 
MiR-7 is an intronic miRNA that resides in the first intron of heterogenous ribonuclear 
protein K gene of chromosome 9 and is conserved across all species. This miRNA, whose 
expression is positively regulated by a homeodomain transcription factor (HoxD10), is 
downregulated in GBM [92, 93]. Kefas and colleagues showed that miR-7 directly targets EGFR, a 
receptor known to be upregulated in more than 60% of primary GBMs [89] and that, along with 
AKT, plays an important role in the development of primary GBM. Its downstream effects of 
miR-7 downregulation are inhibition of apoptosis and promotion of both cellular proliferation 
and growth [89]. In their study, Kefas et al., demonstrated that overexpression of miR-7 reduced 
viability and invasiveness of GBM cells [93]. 
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Two other miRNA that are overexpressed in GBM are miR-221 and miR-222. These 
miRNAs are transcribed as a cluster from chromosome Xp11.3, their expression is coregulated by 
each other and they also share the same mRNA targets. These two miRNAs promote cell growth 
and proliferation through the targeting of p27kip1[94], which is a protein known to promote cell 
cycle arrest through the inhibition of cyclin-dependent protein kinases (CDKs) [89]. 
 Several other miRNAs have been described as being deregulated in glioma. Table 3 
summarizes several miRNAs that are deregulated in GBM, along with several of their targets.  
 
Fig. 11 – Schematic representation of miR-21-influenced signaling pathways. miR-21 inhibits translation of RECK, 
TGFBR, PDCD4, p63, JMY, TOPORS, DAXX and TP53BP2 proteins, therefore regulating apoptosis cell cycle and 
translation in glioblastoma. Adapted from [89]. 
miR-21 
miR-21 
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Table 3 - MiRNAs deregulated in glioblastoma and their validated targets. 
miRNA Type of Expression Validated Targets Reference 
21 High 
PDCD4; TIMP3; RECK; 
DAXX; p63; TGF-β. 
[37, 38, 91] 
7 Low 
EGFR; IRS-1; 
IRS-2; PAK1. 
[92, 93] 
221/222 High p27kip1. [94] 
128 Low 
Bmi-1; EGFR; 
PDGFR. 
[90, 95] 
195 Low CCND1; CCND2; E2F3. [96] 
10b High 
HoxD10; Tiam1; 
KLF4; Bim; TFAP2C; 
p16; p21. 
[97-100] 
 
1.4.3 – The role of miRNAs in the immune response 
The immune response is conventionally divided into adaptive and innate. The adaptive 
immunity, also known as acquired immunity, involves specialized immune cells that mediate a 
fast response when the body is exposed to a recurrent pathogen. On the other hand, innate 
immunity provides the first line of defense against various pathogenic infections and is mediated 
by innate immune cells, such as monocytes, DCs or microglia, and triggers inflammation. Innate 
immune cells detect PAMPs through several conserved pattern recognition receptors, of which 
the TLR family is best characterized. For example, TLR3 recognizes double-stranded RNA, which 
is usually associated with viruses [101], whereas TLR4 recognizes bacterial products, such as LPS 
[102]. In the recognition of pathogens, TLRs recruit adaptor proteins to facilitate the activation 
of downstream signalling cascades, such as the nuclear factor kappa B (NF-κB) and mitogen-
activated protein kinase (MAPK) pathways [103, 104]. These signaling processes lead to the 
expression of inflammatory mediators, such as nitric oxide (NO), cytokines or chemokines, and 
to the expression of several miRNAs [103, 105]. Recent studies have indicated a role for several 
miRNAs such as miR-21, miR-146a, miR-125b, miR-155 or miR-9 in the regulation of 
inflammatory upstream and downstream responses of TLR-activated pathways [106-110]. Table 
4 displays a summary of several miRNAs involved in TLR pathways, their targets and main effects 
on immune cells. 
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Table 4 – MiRNAs involved in the TLR pathways. Adapted from [111]. 
miRNA Target mRNA Effect 
miR-9 NF-kB1/p50 
Transcription by NF-kB 
is decreased 
miR-16 TNF-α 
Decreases levels of 
inflammatory ctyokines 
miR-17-5p, miR-20a, 
miR-106a 
Transcription factor CBF 
Inhibit of monocyte 
maturation 
miR-21 PDCD4, IL12p35 Derepression of IL-10 
miR-27b PPARγ  
miR-105 TLR2  
miR-106 IL-10 
Cooperates with RNA 
binding proteins to decrease IL-10 
miR-125b TNF-α  
miR-145 MAL Inhibits TLR signaling 
miR-146 a TRAF6, IRAK1, IRAK2 
Negative feedback 
regulator of TLR 
signaling 
miR-155 
AID, MyD88, TAB2, IKKε, 
SHIP1, SOCS1, C/EBPBβ 
Overall proinflammatory, 
some feedback 
regulation 
miR-199 IKKβ  
miR-221 TNF-α  
miR-223 TLR3, TLR4 IKKα 
Granulopoiesis and 
monocyte activation 
Let-7i, let-7e TLR4 Downregulates inflammatory signaling 
 
1.4.3.1 – MiRNAs involved in the immune response 
 As previously mentioned, a wide range of miRNAs have been reported as being involved 
in the mechanisms underlying immune response. For these, two functional paradigms have 
emerged: the pro-inflammatory associated miRNAs, of which miR-155 is the most representative 
example; and the anti-inflammatory associated miRNAs, such as miR-21 or miR-146a [112, 113]. 
Despite the array of miRNA reported as being involved in the immune response and in immune 
cell functions, for the scope of this thesis only miR-155 and miR-21 will be discussed in detail. 
Adapted from [111] 
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1.4.3.1 – a) MiR-155 
MiR-155 has been identified as a single primary transcript which is processed from 
within the second exon of the non–protein-encoding gene, bic [114, 115]. This miRNA is involved 
in B-cell differentiation and proliferation and is probably the best characterized miRNA during B 
cell response, being upregulated following the activation of these cells in the germinal centre 
[114]. MiR-155-deficient B cells have defective switching of immunoglobulin (Ig) M to IgG and 
impaired differentiation into plasma cells, resulting in a dysfunctional humoral response to T 
cell-dependent antigenic stimulation. It was reported that miR-155 is involved in the 
downregulation of IgG1 production from B-cells by directly targeting of transcription factor PU.1, 
which is responsible for the transcription of this immunoglobulin [116, 117]. MiR-155 also 
targets activation-induced cytidine deaminase (AID), which is also important for antibody 
production [118]. By targeting PU.1 and AID, miR-155 regulates the differentiation of B cells into 
plasma cells [117] (Fig.12). Furthermore, knockout mice for miR-155 were shown to be  
immundeficient and, after immunization, failed to develop a protective response against 
bacteria [116, 119]. These findings suggest that this miRNA plays an important role in adaptive 
immunity.   
 
 
 
 
 
 
 
 
MiR-155 is also involved in the innate immune response since its expression is increased 
after LPS (via TLR-4) and lipoprotein (via TLR-2) stimulation in monocytes, macrophages or 
microglia [109, 120]. MiR-155 targets Src homology 2 (SH2) domain-containing inositol-5ʹ-
phosphatase (SHIP)1, which is a negative regulator of TLR4 [121] and of the suppressor of 
cytokine signaling (SOCS)1 [120], thus leading to enhanced AKT activation and IFN production 
[121, 122].  
Fig. 12 – MiR-155 regulation of B cell differentiation. MiR-155 targets the transcription factor PU.1 thus leading to 
the downregulation of IgG1 production and inhibiting the differentiation of B cells into plasma cells. Adapted from 
[108]. 
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1.4.3.1 – b) MiR-21 
An increase of miR-21 expression has been observed after sustained inflammatory 
stimuli, similarly to what was found in chronic inflammatory diseases, like lung inflammation due 
to allergic reactions or ulcerative colitis [123, 124]. It has also been shown by Schetter et al. that 
the pro-inflammatory cytokine IL-6 induces the expression of miR-21 in a signal transducer and 
activator of transcription (STAT) 3-dependent manner [125].  
MiR-21 has been proposed as playing an anti-inflammatory role in immune cells such as 
macrophages. In these cells, miR-21 induction via TLR4 was suggested to lead to a decrease of 
PDCD4, a protein required for NF-kB activation and IL-6 transcription [106]. The down-regulation 
of PDCD4 has also been shown to be accompanied by an increase in the levels of the anti-
inflammatory cytokine IL-10 [106]. McCoy and colleagues demonstrated that IL-10 negatively 
regulates the TLR4 signaling pathway by targeting miR-155 [126]. As mentioned before, miR-155 
targets SHIP1 which is a negative regulator of TLR4. These authors have also demonstrated that 
IL-10 increases SHIP1 levels by inhibiting miR-155 expression. It has been proposed that the 
expression levels of miR-155 increase initially due to TLR4 activation, thus resulting in a down-
regulation of SHIP1 and TLR4 signaling potentiation. Immediately after TLR4 stimulation, the 
amounts of PDCD4 within the cells would still be sufficient to activate NF-kB and keep IL-10 
levels down. However, as suggested, with the raising levels of miR-21, the levels of PDCD4 would 
tend to decrease, which may result in a decrease of NF-kB activation and IL-6 expression, and an 
increase of IL-10 levels. The high levels of IL-10 would then lead to a decrease in miR-155 levels, 
in a STAT3 dependent manner [126], thereby restoring SHIP1 levels and limiting TLR4 signaling 
(Fig. 13) [83, 127]. Taken together, these results suggest that miR-21 might have a late anti-
inflammatory role in TLR4 mediated immune responses. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13 – Regulation of TLR4 signaling by miR-21 and 
miR-155. TLR4 signalling increases miR-155 levels, 
which leads to a downregultion of SHIP1 (a negative 
regulator of TLR4 signalling). Later, TLR4 activation 
also increases the level of miR-21, which targets the 
mRNA PDCD4, thus leading to an increase in the 
production of IL-10. IL-10 then feeds back on the 
pathway and specifically inhibits the induction of miR-
155, leading to an increase in SHIP1 levels and thus 
inhibiting TLR4 signalling. Adapted from [127]. 
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2.1 – Objectives 
 
 
 
 To evaluate the effect of glioma cells on microglia activation, namely microglia mediated 
immune response to neoplastic cells; 
 
 To evaluate the effect of miR-21 silencing in microglia cells on the immune response 
mediated by these cells, namely the production of pro-inflammatory mediators and pro-
inflammatory miRNA; 
 
 To evaluate the effect of how miR-21 silencing in microglia on glioma cell death. 
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3.1 – Methods 
3.1.1 – Cell lines and culturing conditions 
The GL261 mouse glioma cell line and the HEK293T human embryonic kidney cell line 
were maintained in DMEM containing 4.5 g/L glucose (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco, Paisley, Scotland), 100 
U/mL penicillin (Sigma), 100 μg/mL streptomycin (Sigma), 10 mM HEPES and cultured at 37°C 
under a humidified atmosphere containing 5% CO2. The N9 immortalized mouse microglia cell 
line was maintained in RPMI-1640 medium (Gibco, Paisley, Scotland) containing 5.4 g/L glucose 
(Invitrogen, Carlsbad, CA, USA) supplemented with 5% heat inactivated FBS (Gibco, Paisley, 
Scotland), 100 U/mL penicillin (Sigma), 100 μg/mL streptomycin (Sigma) and cultured at 37°C 
under a humidified atmosphere containing 5% CO2. 
 
3.1.2 – Lentiviral production and cell transdution 
 
Lentiviruses encoding the anti-miR-21 shRNA and GFP or a control GFP encoding 
sequencing were produced in HEK 293T cells with a four-plasmid system, as previously described 
[128]. The lentiviral particles were produced and resuspended in phosphate-buffered saline 
solution (PBS) containing 1% bovine serum albumin (BSA). The viral particle content of each 
batch was determined by assaying HIV-1 p24 antigen using an ELISA kit (RETROtek, Gentaur, 
Paris, France). The viral stocks were stored at -80ºC until use. 
For the lentiviral transduction of N9 cells, cells were plated into 6-well plates at a final 
concentration of 1 x 105 cells/well. Twenty-four hours after plating, 10 ng of virus coding for 
either anti-miR-21 shRNA or control GFP were added per 1x105 cells; 8 μg of polybrene 
(hexadimethrine bromide) were also added to each well in order to increase the efficiency of 
infection. The cell culture medium was replaced 6 hours after infection and cells were further 
grown for 48 hours. After this period, cells were plated into 10-cm dishes. Infected cells were 
selected by growing cells in culture medium containing 1 µg/mL of puromycin. With this 
procedure, it was possible to generate two new cell lines: one stably expressing GFP and 
reduced levels of miR-21, which was named N9 21; and another one expressing only GFP 
(control cell line), which was named N9 GFP. 
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3.1.3 – Lipoplex preparation and cell transfection 
 
For cell transfection with anti-miR-21 oligonucleotides, lipoplexes were prepared using 
DLS liposomes, as described previously [129]. Briefly, DLS liposomes were prepared by adding 1 
mg of dioctadecylamidoglycylspermidine (DOGS) (Promega, Madison, WI) and 1 mg of dioleoyl 
phosphatidylethanolamine (DOPE) (Sigma, Munich, Germany) dissolved in 40 μL of 90% ethanol, 
followed by the addition of 360 μL of sterile H2O; the mixture was subjected to a short vortex 
and further incubated for 30 min at room temperature in order to allow liposome formation. 
The final lipid concentration was 5 mg/ml (2.5 mg of DOGS and 2.5 mg of DOPE). Lipoplexes 
were prepared by gently mixing 10 μg of oligonucleotides with 76 μL of DLS liposomes 
containing 190 μg of lipid followed by incubation for 30 min at room temperature. DLS 
lipoplexes were prepared fresh for every experiment. N9 cells were plated at 1x105 cells/well 
into 12-well plates, 24h before each experiment. On the day of the transfection, the cell medium 
was changed to OPTIMEM (Gibco) and the lipoplexes were added to cells, at a final 
concentration of 100 nM oligonucleotides/well. After a 4-hour incubation period, OPTIMEM was 
replaced with fresh RPMI medium and cells were further cultured for 24h or 48h. 
3.1.4 – Liposomes and lipoplex characterization 
DLS liposome and lipoplex size distribution was assessed by photon correlation 
spectroscopy, using an N5 submicrometer particle size analyzer (Beckman Coulter, Miami, FL, 
USA). Measurements were made at a 90° angle and at 20°C. 
3.1.5 – Assessment of cell transduction/transfection by flow cytometry 
 
To evaluate the extent of cell transduction, N9, N9 21 and N9 GFP cells were plated into 
12-well plates at a cell density of 1 x 105 cells/well. Twenty-four hours after plating, cells were 
washed twice with PBS, detached by exposure to trypsin (5 min, 37oC) and washed once more 
with PBS. Cells were then ressuspended in 1 mL of cold PBS and immediately analyzed in a FACS 
Calibur flow cytometer (BD, Biosciences). GFP fluorescence was evaluated in the FL-1 channel 
and a total of 50.000 events were collected (unless stated otherwise).  
 To evaluate the efficiency of cell transfection with DLS lipoplexes, N9 cells were plated 
into 12-well plates at a density of 1 x 105 cells/well 24h before transfection. Twenty-four hours 
after transfection with FAM-labeled anti-miR-21 oligonucleotides, cells were subjected to the 
same procedure described above. In order to quench the fluorescence of the lipoplexes attached 
to the cell surface, which were not internalized, 10 µL of 0.4% Trypan blue were added to 200 µL 
of cell suspension. FAM fluorescence associated to the anti-miR-21 oligonucleotides was 
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evaluated in the FL-1 channel and a total of 50.000 events were collected (unless stated 
otherwise) for both Trypan blue treated and untreated cells.  
All data were analyzed using the Cell Quest software (BD). 
3.1.6 – Assessment of cell transfection by confocal microscopy 
 
To confirm the extent of cellular internalization of the DLS lipoplexes, N9 cells were 
plated into ibiTreat 8-well slides (Ibidi, Munich, Germany) at a density of 1x104 cells/well 24h 
before transfection with DLS lipoplexes. Twenty-four hours after transfection, cells were rinsed 
twice with PBS, stained with the DNA binding dye Hoechst 33342 (Molecular Probes, Oregon, 
USA) (1 μg/mL) for 5 min (in the dark), rinsed twice with PBS and maintained alive in this saline 
solution for image acquisition. Confocal images were acquired in a point scanning confocal 
microscope Zeiss LSM 510 Meta (Zeiss, Germany), using a 60 x oil objective and the Blue 
(405nm), Green (488nm) and DIC (633nm) lasers. Digital images were acquired using the LSM 
510 META software. All instrumental parameters pertaining to fluorescence detection and image 
analyses were held constant to allow sample comparison. 
3.1.7 – Evaluation of cell viability following transfection  
 
Cell viability was assessed under the different experimental conditions by a modified 
Alamar Blue assay. Briefly, 24 h post-transfection, N9 cells were incubated with RPMI containing 
10% (v/v) of Resazurin (Sigma, Munich, Germany). After 1 h incubation at 37oC, the absorbance 
of the medium was measured at 570 and 600 nm. Cell viability was calculated as a percentage 
with respect to non-transfected control cells, according to equation 1: 
 
              (            )   
                   
         
          
  
     (Equation 1) 
 
Where          and          are the absorbances of the transfected cells, and 
        
  and         
  those of control cells at the indicated wavelengths.  
 
3.1.8 – Conditioned medium production 
 
Two types of microglia conditioned medium were produced: non-activated microglia 
conditioned medium and activated microglia conditioned medium. In order to produce non-
activated medium, fresh RPMI medium was added to N9 cells and collected following 24 h of 
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contact with the cells. A similar procedure was used to produce activated medium, except that 1 
μg/mL of LPS was added to the culture medium. After collection, both conditioned mediums 
were filtered using a 0.22 μm filter to remove debris, diluted with the same amount of fresh 
DMEM (glioma culture medium) and kept at 4oC until use. 
Glioma conditioned medium was produced by adding fresh DMEM to GL261 cells, and 
collected after 48 h of contact with the cells. After collection, the medium was filtered using a 
0.22 μm filter to remove debris and kept at 4oC until use. 
3.1.9 – Nitrite quantification 
 
Nitric oxide production was assessed by the Griess Reagent System (Promega 
Corporation, Madison, WI), a colorimetric assay that detects the presence of nitrite (NO2), a 
stable reaction product of nitric oxide (NO) and molecular oxygen in the cell medium. Briefly, 50 
µL of cell medium, collected from each well were incubated for 5 min with 50 µL sulfanilamide, 
followed by a second incubation of 5 min with 50 µL of N-1-napthylethylenediamide (NED). The 
optical density of the samples was measured at 535 nm in a microplate reader and the nitrite 
concentration in each sample was determined by comparison with a standard curve obtained for 
a solution of sodium nitrite prepared in culture medium. Results were normalized with total 
protein levels of each sample. 
3.1.10 – Extraction of total RNA and cDNA synthesis 
 
Total RNA, including small RNA species, was extracted from N9 microglia cells using the 
miRCURY Isolation Kit – Cells (Exiqon), according to the recommendations of the manufacturer 
for cultured cells. Briefly, after cell lysis, the total RNA was adsorbed to a silica matrix, washed 
with the recommended buffers and eluted with 35 µL RNase-free water by centrifugation. After 
RNA quantification, cDNA conversion for miRNA quantification was performed using the 
Universal cDNA Synthesis Kit (Exiqon). For each sample, cDNA for miRNA detection was 
produced from 20 ng total RNA according to the following protocol: 60 min at 42oC followed by 
heat-inactivation of the reverse transcriptase for 5 min at 95oC. The resulting cDNA was diluted 
40 times with RNase-free water before quantification by qPCR. Synthesis of cDNA for mRNA 
quantification was performed using the NZY First-Strand cDNA Synthesis Kit (NZYtech, Lisbon, 
Portugal) employing 1 µg total RNA for each reaction, by applying the following protocol: 10 min 
at 25oC, 30 min at 50oC and 5 min at 85oC. After transcription, the samples were further 
incubated for 20 min at 37oC with an RNase H (from E. colli) to specifically degrade the RNA 
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template in cDNA:RNA hybrids after the first-strand cDNA synthesis. Finally, the obtained cDNA 
was diluted 10 times with RNase-free water before quantification by qPCR. 
3.1.11 – Quantitative real time PCR 
Quantitative PCR was performed in a StepOnePlus thermocycler (Applied Biosystems) 
using 96-well microtitre plates. For miRNA quantification the miRCURY LNATM Universal RT 
microRNA PCR system (Exiqon) was used in combination with pre-designed primers (Exiqon) for 
miR-21, and miR-155.The small nuclear RNA snord110 was used as a reference. A master mix 
was prepared for each primer set, according to the recommendations for the real-time PCR 
setup of individual assays suggested in this kit. For each reaction, 6 µL of master mix were added 
to 4 µL template cDNA. All reactions were performed in duplicate (two cDNA reactions per RNA 
sample) at a final volume of 10 µL per well, using the StepOnePlus software (Applied 
Biosystems). The reaction conditions consisted of polymerase activation/denaturation and well 
factor determination at 95oC for 10 min, followed by 45 amplification cycles at 95oC for 10 s and 
65oC for 1 min (ramp-rate 1,6oC/s).  
For mRNA quantification, the iQ SYBR Green Supermix Kit (Bio-Rad) was used. The 
primers for the target genes (PDCD4, iNOS, IL-6, IL-1β and TNF-α) and for the reference gene 
(HPRT) were pre-designed by Qiagen (QuantiTect Primer, Qiagen, Hilden, Germany). A master 
mix was prepared for each primer set, containing a fixed 6.5 µL volume of SYBR Green Supermix 
and the appropriate amount of each primer to yield a final concentration of 150 nM. For each 
reaction, 10 µL of master mix were added to 2.5 µL of template cDNA. All reactions were 
performed in duplicate (two cDNA reactions per RNA sample) at a final volume of 12.5 µL per 
well, using the StepOnePlus software (Applied Biosystems). The reaction conditions consisted of 
enzyme activation and well-factor determination at 95oC for 1 min and 30 s, followed by 40 
cycles at 95oC for 10 s (denaturation), 30 s at 55oC (annealing), and 30 s at 72oC (elongation). 
 For both miRNA and mRNA quantification, a melting curve protocol was started 
immediately after amplification and consisted of 1 min heating at 55oC followed by 80 steps of 
10 s, with a 0.5oC increase at each step. The miRNA and mRNA fold change with respect to 
control samples was determined by the Pfaffl method, taking into consideration the different 
amplification efficiencies of all genes and miRNAs analysed in each experiment. The 
amplification efficiency for each target or reference RNA was determined according to the 
formula: E = 10(-1/S) – 1, where S is the slope of the obtained standard curve. 
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3.1.12 – Fluorescence in situ hybridization (FISH) 
FISH was performed in cultured adherent cells as described by Cardoso et. al [120]. 
Briefly, wild type, GFP and 21 N9 cells were plated onto multi-chambered coverglass slides 
Millicell EZ SLIDE (Merck KGaA, Darmstadt, Germany) appropriate for confocal microscopy 
imaging. Twenty-four hours after plating, the cells were washed with PBS, fixed with 4% 
paraformaldehyde for 30 min at room temperature and permeabilized at 4oC in 70% ethanol for 
4 h. Cells were then incubated with a fresh acetylation solution (0.1 M triethanolamine and 0.5% 
(v/v) acetic anhydride) for 30 min at room temperature, rinsed twice in TBS and pre-hybridized 
in the absence of the LNA probe in hybridization buffer (50% formamide, 5 x SSC, 5 x Denhardt’s 
solution, 250 µg/ml yeast tRNA, 500 µg/ml salmon sperm DNA, 2% (w/v) blocking reagent, 0.1% 
CHAPs, 0.5% Tween) for 2 h at a temperature 22–25oC below the melting temperature (TM) of 
the probe. The hybridization step was carried out using the DIG-labelled (digoxigenin-labelled) 
LNA probes for miR-21 at the same temperature overnight. A scrambled probe was used as 
control. Three stringency washes were performed at the same temperature used for probe 
hybridization to completely remove the non-hybridized probe. Endogenous peroxidase activity 
was inactivated by incubation in 3% hydrogen peroxide in TBS with 0.1% Tween-20 (TBS-T) for 
30 min, followed by three washes with TBS-T. The slides were then placed in blocking solution 
(TBS-T, 10% heat-inactivated goat serum, 0.5% blocking agent) for 1 h at room temperature and 
incubated for the same period of time with an anti-DIG antibody (Roche, Amadora, Portugal) 
conjugated with hydrogen peroxidase. To amplify the antibody signal, slides were further 
incubated with a TSA plus Cy3 (PerkinElmer, Waltham, MA) solution for 10 min in the dark, in 
accordance with the manufacturer’s protocol. The cells were finally stained with the fluorescent 
DNA-binding dye Hoechst 33342 (Molecular Probes, Oregon, USA) (1 µg/ml) for 5 min in the 
dark, washed with cold PBS, and mounted in Mowiol (Fluka; Sigma). Confocal images were 
acquired in a point scanning confocal microscope Zeiss LSM 510 Meta (Zeiss, Göttingen, 
Germany), with a 63 x oil objective. Digital images were acquired using the LSM 510 META 
software. All instrumental parameters pertaining to fluorescence detection and image analyses 
were held constant to allow sample comparison. 
 
3.1.13 – Western Blot analysis 
 
Total protein extracts were prepared from cultured N9 cells by lysing the cells at 4oC in 
RIPA lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 50 mM EDTA, 0.5% sodium deoxycholate, 1% 
Triton X-100) containing a protease inhibitor cocktail (Sigma), 2 mM DTT and 0.1 mM PMSF. The 
concentration of protein lysates was determined using the Bio-Rad Dc protein assay (Bio-Rad). 
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Briefly, 20 μg of total protein were resuspended in loading buffer (20% glycerol, 10% SDS, 0.1% 
bromophenol blue), incubated for 5 min at 95oC and loaded into a 10% polyacrylamide gel for 
electrophoretic separation. After electrophoresis, the proteins were blotted into a PVDF 
membrane, blocked in 5% nonfat milk for 1 hour, incubated overnight at 4oC with an anti-PDCD4 
antibody (clone D29C6, Cell signaling; 1:1000) and with the appropriate alkaline phosphatase 
labeled-secondary antibody (1:20000) (Amersham, Uppsala, Sweden) for 2 hours at room 
temperature. Equal protein loading was verified by reprobing the membrane with an anti-β-actin 
antibody (1:10000) (Sigma) and with the appropriate alkaline phosphatase labeled-secondary 
antibody (1:20000) (Amersham, Uppsala, Sweden) for 2 hours at room temperature. After 
antibody incubation, the membranes were washed several times with TBS-T (Bio-Rad), 
incubated with the enzyme substrate ECF (Amersham Biosciences, UK) for 5 min at room 
temperature and then submitted to fluorescence detection at 570 nm using a VersaDoc Imaging 
System Model 3000 (Bio-Rad). The analysis of band intensity was performed using the ImageJ 
software. 
 
3.1.14 – Caspase 3/7 induction assay 
 
 Caspase-3/7 activity was assessed using the SensoLyte homogenous AMC caspase-3/7 
assay (AnaSpec, San Jose, CA, USA). Briefly, 48 h after incubation with activated or non-activated 
microglia conditioned medium, derived from all three microglia cell lines, GL261 cells were 
collected and lysed, according to the instructions of the manufacturer. The cell supernatant and 
caspase substrate (Ac-DEVD-AMC) were mixed, according to the recommendation of the 
manufacturer, and further incubated in a black 96-well plate for 40 min at room temperature 
(under shaking). The production of the AMC fluorophore, released as a result of caspase activity 
on the substrate, was measured for a period of 5 hours using a microplate reader (SpectraMax 
Plus 384, Molecular Devices) at excitation/emission wavelengths of 354/442 nm, respectively. 
Results, presented as relative fluorescence units (RFU), represent the fold change ratio of each 
experimental condition with respect to control (untreated cells), and were normalized 
considering the total number of cells in each condition. 
3.1.15 – Evaluation of apoptotic cell death 
 
The detection of apoptosis was performed in GL261 cells using the Annexin V-PE 
Apoptosis Detection Kit (Calbiochem, Merck-Millipore, Darmstadt, Germany). Briefly, 48 hours 
after incubation  with activated or non-activated microglia conditioned medium derived from all 
three microglia cell lines, cells were detached using trypsin, washed twice with cold PBS and 
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resuspended in PBS. From this suspension, 1 x 105 cells were transferred to 5 mL polystyrene 
tubes, centrifuged at 1500 rpm for 5 min and resuspended in 200 μL of Incubation Buffer (10 
mM HEPES, 150 mM NaCl, and 2 mM CaCl2, pH 7.4). Following this step, the cells in each tube 
were incubated for 10 min at room temperature with 2 μL of Annexin V-PE and 5 μL of 7-AAD 
(Sigma). The samples were immediately analyzed in a FACS Calibur flow cytometer. PE 
fluorescence was evaluated in the FL-2 channel, 7-AAD was evaluated in the FL-3 and a total of 
10.000 events were collected per sample. The data were analyzed using the Cell Quest software. 
3.1.16 – Statistical analysis 
 
All data are presented as mean ± standard error of the mean (SEM) of at least three 
independent experiments, each performed in duplicate, unless stated otherwise. One way 
analysis of variance (ANOVA) combined with the Tukey posthoc test was used for multiple 
comparisons in cell culture experiments (unless stated otherwise) and considered significant 
when p< 0.05. Statistical differences are presented at probability levels of p< 0.05, p< 0.01 and 
p< 0.001. Calculations were performed with standard statistical software (Prism 5, GraphPad, 
San Diego, CA, USA). 
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4.1 – Glioma cells modulate microglia-mediated immune response 
 The interaction of glioma with microglia has been a matter of debate in the past few 
years. Some studies suggest that microglia loses their immune ability when in contact with 
glioma cells. However other studies suggest that microglia does not lose their innate immune 
response ability, but their function as antigen presenting cells (APCs) impaired.  
In order to clarify how glioma cells modulate microglia mediated-immune response, we 
incubated N9 microglia cells for 48 h with glioma conditioned medium obtained from GL261 cells 
and assessed the expression of two pro-inflammatory cytokines, IL-1β and TNF-α (Fig.14a and b) 
in N9 cells by qPCR. We observed that the levels of the mRNA of both of these cytokines were 
significantly increased in the presence of glioma cells conditioned medium. Moreover, we 
observed a slight decrease in the levels of the suppressor of cytokine signaling (SOCS)-1 mRNA 
(Fig.14c), although this decrease was not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14 – Assessment of cytokine production by N9 microglia cells following incubation with conditioned medium 
from glioma cells. N9 cells were plated 24 h before the 48 h incubation with glioma conditioned medium. (a), (b) 
and c – After incubation, total RNA was extracted and the mRNA levels of the pro-inflammatory cytokines IL-1β (a) 
and TNF-α (b), and the suppressor of cytokine signaling (SOCS)-1 (c) were assessed using qPCR. Results are 
representative of three independent experiments performed in duplicate. Paired one-tailed t-test was used to 
calculate statistical significance *  – P < 0.05. 
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In addition to assess cytokine mRNA levels, we quantified, by qPCR the mRNA levels of 
the inducible nitric oxide synthase (iNOS), an enzyme that is responsible for the production of 
nitric oxide and known to be upregulated in the presence of certain pro-inflammatory stimulus. 
A significant increase in the mRNA levels of this protein was observed after N9 cell incubation 
with glioma conditioned medium, and an even larger increase was detected when the cells were 
stimulated with LPS following incubation with glioma cells conditioned medium (Fig.15a). 
Furthermore, and in agreement with the observed upregulation of iNOS, we observed, using the 
Griess reaction, an increase in the production of nitric oxide in the N9 cells exposed to glioma 
conditioned medium 24 h before the incubation with LPS (Fig.15b). However, incubation with 
the conditioned medium by itself was not sufficient to increase NO production in N9 cells, 
despite the significant increase in iNOS mRNA levels. 
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Fig. 15 – Evaluation of iNOS expression and nitric oxide production following N9 incubation with conditioned 
medium from glioma cells. Twenty-four hours after plating, N9 cells were incubated with glioma conditioned 
medium. (a) – Twenty-four hours after incubation with glioma conditioned medium, 1 µg/mL of LPS was added to 
the cells, and 24h later, total RNA was extracted and induced nitric oxide synthase (iNOS) mRNA levels were 
assessed using qPCR. (b) – Twenty-four hours after incubation with glioma conditioned medium, 1 µg/mL of LPS was 
added to the cells. Cells were further incubated with glioma conditioned medium, in the presence or absence of 
LPS, for more 24h. Twenty-four hours after LPS incubation, NO production was assessed using the Griess test and 
the NO concentrations obtained were normalized with the total protein levels of each sample. Results are 
representative of three different experiments performed in duplicate.; * – P < 0.05, ** – P < 0.01, *** – P < 0.001. 
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Finally, using qPCR we assessed the levels of two miRNAs, miR-21 and miR-155. As 
shown in Fig.16, following incubation of microglia cells with glioma conditioned medium for 48 
h, miR-155 was slightly upregulated and miR-21 was significantly upregulated which indicates 
that both these miRNAs may play a role in the increase of cytokine expression and NO 
production in the presence of glioma cells conditioned medium. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b 
Fig. 16 – Evaluation of miR-21 and miR-155 expression in N9 cells following incubation with conditioned medium 
from glioma cells. (a) and (b) – N9 cells were incubated (for 48 h) with glioma conditioned medium. After 
incubation, total RNA were extracted and miRNAs 21 and 155 levels were determined by qPCR using specific LNA 
probes for the mature form of these miRNA. Results are presented as miRNA fold change and are representative of 
three independent experiments; Paired one-tailed t-tes was used to calculate statistical significance; ** – P < 0.01. 
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4.2 – MiR-21 silencing influences the microglia-mediated innate immune 
response 
4.2.1 – Evaluation of the lentiviral transduction efficiency of N9 cells 
 MiR-21 has been suggested to play a role in the regulation of TLR4-mediated immune 
response. Therefore, in order to clarify if this miRNA also plays a role in the innate immune 
response against glioma cells, we transduced N9 microglia cells with a lentivirus encoding an 
anti-miR-21 shRNA and GFP. Control experiments were performed in parallel by N9 cells with a 
lentivirus encoding only GFP. With this procedure, we generated two new cell lines which we 
called N9 21 and N9 GFP, respectively. The percentage of transduced cells was assessed by flow 
cytometry based on GFP expression (Fig.17a and b). N9 21 cells presented approximately 70% of 
cell transduction, while N9 GFP cells presented approximately 40% of cell transduction (Fig.17b). 
Transduction of N9 cells with the lentivirus encoding the anti-miR-21 shRNA also conferred them 
resistance to puromycin, thus allowing to chemically select N9 transduced cells with this 
antibiotic. On the other hand, the lentivirus encoding only GFP did not confer resistance to this 
antibiotic and, therefore, the percentage of transduced cells with this lentivirus could not be 
further increased. However, by testing the transduction of N9 GFP cell line over the course of 
several weeks, we were able to observe the presence of a stable population of N9 GFP cells 
(±40%) (Fig.17c).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 17 – Lentiviral-mediated transduction of N9 cells. (a) – Flow 
cytometry histogram showing the profile of cell transduction of the 
different cell lines (black – non-transduced cells (N9); dark grey – Control 
N9 cells transduced only with GFP (N9 GFP); light grey – N9 cells 
transduced with anti-miR-21 shRNA and GFP (N9 21); (b) – Percentage of 
transduced cells after puromicyn treatment; (c) – Percentage of GFP
+
 cells 
in the N9 GFP cell line over time. 
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Quantification of miR-21 expression levels in the wild type and transduced N9 cells by 
qPCR revealed a significant decrease in the expression of this miRNA in N9 21 cells, with respect 
to wild type N9 cells, which was not observed in N9 GFP cells (Fig. 18a). These results were in 
agreement with our observations by FISH using an anti-miR-21 probe (Fig.18b). 
 As observed, in the presence of an inflammatory-stimulus, such as LPS, miR-21 levels 
increased in wild type and transduced cells. However, in N9 21 cells, the levels of miR-21 
increased in a smaller extent, when compared to control cells (N9 GFP; Fig.18), although this 
difference was not found to be statistically significant.  
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Fig. 18 – Assessment of miR-21 levels in wild type, GFP and 21 N9 cells; Wild type, GFP and 21 N9 cells were 
incubated for 24 h either in the absence or presence of 1 µg/mL LPS. (a) – Following cell incubation with LPS, total 
RNA was extracted and miR-21 levels were determined by qPCR using specific LNA probes for the mature form of this 
miRNA. Results are presented as miR-21 fold change with respect to resting N9 wild type cells and are representative 
of four independent experiments; **P < 0.01 and ***P < 0.001. (b) – Levels of miR-21 were also analyzed by FISH in 
non-stimulated wild type (i), GFP (ii) and 21 (iii) N9 cells. MiR-21 was labeled using an anti-miR-21 DIG-conjugated 
LNA-based probe, specific for the mature form of this miRNA (i, ii and iii). A scramble DIG-conjugated LNA-based 
probe was used as control (iv, v and vi). Expression of miR-21 (red) was detected using an anti-DIG antibody and the 
TSA Cy3 signal amplification system. The cell nuclei (blue) were labelled with Hoescht 33342 (Molecular Probes, 
Oregon, USA). Representative confocal microscopy images of all experimental conditions are presented at a 600 x 
magnification.  
a 
b 
N9 GFP N9 21 
i ii iii 
iv v vi 
N9  
Carlos Custódia 
 
49 
 
4.2.2 – Evaluation of microglia immune response following lentiviral miR-21 silencing 
In order to evaluate the effect of miR-21 silencing in microglia-mediated immune 
response, N9 cells were challenged with inflammatory stimulus, and the quantification of nitric 
oxide (NO) production and cytokine expression were assessed. We observed that, 24h after 
stimulation with LPS, NO production of N9 21 cells was significantly reduced with respect to wild 
type (N9) and control cells (N9 GFP; Fig. 19a). Regarding the expression of pro-inflammatory 
cytokines, a significant decrease in the levels of the pro-inflammatory cytokine IL-6 was 
observed in resting N9 21 cells, with respect to resting N9 GFP cells. Despite the differences 
revealed in the resting state no significant differences were observed when the different cell 
lines were activated through incubation with LPS. However, in stimulated N9 21 cells, IL-6 mRNA 
levels were still lower than those observed in N9 GFP (Fig.19b). In addition, we were not able to 
observe significant differences in the mRNA levels of the pro-inflammatory cytokines IL-1β, TNF-
α and IFN-β (data not shown for TNF-α and IFN-β) between N9 GFP and N9 21 cells, either in 
resting or LPS-stimulated conditions (Fig.19c).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19 – Effect of miR-21 silencing in the pro-inflammatory response of wild type and lentiviral transduced N9 
cells. Wild type, GFP and 21 N9 cells were incubated for 24h, either in the absence or in the presence of 1µg/mL 
LPS. Following cell incubation with LPS (a) nitric oxide levels were assessed using the Griess test and the NO 
concentrations obtained were normalized with the total protein levels of each sample; (b) IL-6 and (c) IL-1β mRNA 
levels were determined for all cell lines in both resting and activated conditions by  q-PCR. Q-PCR results are 
presented as mRNA fold change with respect to resting N9 wild type cells; Results are representative of four 
independent experiments. ns – non-significant, * – P < 0.05, *** – P < 0.001. 
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Taken together, these results show that miR-21 is involved in the nitric oxide production 
pathway and is important for IL-6 expression in N9 cells. However, miR-21 silencing does not 
affect IL-1β (and other cytokines) levels, both in resting and LPS-activated microglia, which 
suggests that this cytokine is not directly regulated by miR-21. 
4.2.3 – Evaluation of PDCD4 levels following miR-21 silencing   
PDCD4 is a validated direct target of miR-21 and has been also been suggested to be 
involved in the regulation of IL-10 production after TLR4 stimulation. Therefore, we evaluated 
the mRNA and protein levels of PDCD4 in N9 cells following miR-21 silencing. As illustrated in 
Fig.20, an increase in both PDCD4 mRNA and protein levels was observed in resting N9 21 cells, 
with respect to control cells (N9 GFP). In addition, 24 h after LPS stimulation, a significant 
decrease in both PDCD4 mRNA and protein levels was obtained, in the three cell lines, which is 
in agreement with the results previously reported by Sheedy et. al. [106]. Despite this decrease, 
which was expected due to the increase of miR-21 levels in the three cell lines in the presence of 
LPS (Fig.18a), PDCD4 mRNA levels were significantly higher in activated N9 21 cells, with respect 
to activated N9 GFP cells (Fig.20a), which may be attributed to the difference in miR-21 levels in 
these two cells lines.  However, following miR-21 silencing, no significant differences in PDCD4 
levels between LPS stimulated N9 21 and N9 GFP cells could be detected (Fig.20b and c 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20 – Assessment of PDCD4 levels following miR-21 silencing.  Wild type, GFP and 21 N9 cells were incubated in 
the absence or presence of 1µg/mL LPS for 24h. After cell incubation, total RNA and protein were extracted. (a) 
PDCD4 mRNA levels were quantified using q-PCR and (b) PDCD4 protein levels were determined using western blot. 
Results are presented as mRNA or protein fold change  with respect to resting N9 wild type cells; (c) Representative 
western blot image showing PDCD4 levels in all cell lines in resting and activated conditions. Results are 
representative of three independent experiments. ns – non-significant, * - P < 0.05, ** - P < 0.01. 
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4.2.4 – Transfection of N9 cells with DLS lipoplexes 
Although lentiviruses have the ability to efficiently transduce the N9 cell line, the 
expression of the anti-miR-21 shRNA in these cells might not be sufficient to clearly assess the 
role of this miRNA in the microglia-mediated immune response. Therefore, in order to obtain a 
stronger, although transient silencing of miR-21, N9 cells were transfected with DLS lipoplexes at 
a final anti-miR-21 oligonucleotide concentration of 100 nM. DLS lipoplexes have already been 
described by us and others as being an efficient vector for the delivery of antisense 
oligonucleotides to different cell lines [129].  
Before performing the transfection experiments, DLS liposomes and lipoplexes were 
characterized in terms of their size, since this parameter plays an important role in transfection 
efficiency. The size of liposomes and lipoplexes was assessed using photon correlation 
spectroscopy. Freshly prepared DLS liposomes and DLS lipoplexes obtained from freshly 
prepared DLS liposomes exhibited a unique particle population with a size of approximately 
200nm and 270 nm, respectively.  On the other hand, one week old DLS liposomes exhibited two 
distinct populations of particles; one major population (81.2%) of approximately 270 nm, and a 
smaller one (18.8%) of approximately 50 nm. DLS lipoplexes prepared with one week old DLS 
liposomes exhibited a unique population of particles with approximately 240 nm in size (Fig. 21). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21 – Physicochemical characterization of DLS liposomes and lipoplexes. Analysis of DLS liposome and lipoplex 
size was performed immediately (Day 0) and 7 days (Day 7) after liposome preparation.  DLS lipoplex were produced 
from Day 0 or Day 7 DLS liposomes and size analysis was performed immediately after preparation. Particle size was 
assessed through photon correlation spectroscopy using a N5 submicrometer particle size analyzer (Beckman 
Coulter, Miami, FL, USA). 
D
LS
 li
po
so
m
es
D
LS
 li
po
pl
ex
D
LS
 li
po
so
m
es
D
LS
 li
po
pl
ex
0
50
100
150
200
250
300
0 Days 7 Days
81.2%
18.8%
100%
100%
100%
P
a
rt
ic
le
 s
iz
e
 (
n
m
)
Role of miR-21 in the regulation of microglia immune response to glioma 
 
52 
 
As shown in Fig.22, following 24 h incubation of DLS lipoplexes (complexes of liposomes 
with FAM-labeled anti-miR-21 oligonucleotides) with N9 cells, approximately 85% of lipoplex 
internalization was achieved as assessed by flow cytometry (Fig.22a and c). Similar results were 
obtained from parallel experiments in which trypan blue was added to quench the fluorescence 
of the non-internalized lipoplexes, which suggest that the majority of the lipoplexes bound to 
the cell surface were internalized (Fig.22b and c). Efficient lipoplex internalization and efficient 
endosomal release of the anti-miR-21 oligonucleotides 24 h after transfection were confirmed 
through confocal microscopy analysis (Fig.23). 
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Fig. 22 – Evaluation of DLS lipoplex internalization in N9 cells. N9 cells were transfected with DLS liposomes 
complexed with FAM-labeled anti-miR-21 oligonucleotides, at an oligonucleotide final concentration of 100 nM. (a) 
The percentage of cells that internalized the DLS lipoplexes was assessed by flow cytometry 24h after transfection.. 
(b) Following the first acquisition of 50.000 events per sample and in order to quench the fluorescence of non-
internalized lipoplexes, 10 µL of trypan blue were added to 200 µL of cell suspension and a second acquisition was 
performed for the same number of events. (c) Flow cytometry results are presented as the percentage of cells that 
bind and internalized FAM-labelled oligonucleotides. 
– Trypan Blue 
+ Trypan Blue 
Carlos Custódia 
 
53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantification of miR-21 levels by qPCR revealed that the expression of this miRNA was 
completely abolished in N9 cells transfected with DLS liposomes complexed with FAM-labeled 
anti-miR-21 oligonucleotide (at a final concentration of oligonucleotide of 100 nM), with respect 
to the non-transfected or the scramble-transfected cells (Fig.24). As shown in Fig.24, after cell 
incubation with LPS, an increase in miR-21 levels could be observed in non-transfected cells, but 
not in cells transfected with anti-miR-21 oligonucleotides, suggesting that miR-21 was 
completely silenced even in the presence of a strong activating stimulus. However, after LPS 
stimulation, a decrease in miR-21 levels was observed in cells transfected with scramble 
oligonucleotides with respect to control cells. This suggests the presence of unspecific effects 
due to the DLS transfection process or to the fact that the scramble oligonucleotide employed in 
these experiments was able to interact with miR-21 (Fig.24). 
Fig. 23 – Evaluation of DLS lipoplex internalization and cytoplasmic oligonucleotide release in N9 cells. Confocal 
microscopy was used to confirm lipoplex (green) internalization and efficient endosomal realese 4h (i and iii) and 
24h (ii and iv) after transfection,  Cell nucleus (blue) were stained with Hoechst 33342 (Molecular Probes, Oregon, 
USA). Representative confocal microscopy images of all experimental conditions are presented at a 600 x 
magnification. Results are representative of three independent experiments. 
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4.2.5 – Evaluation of cell viability following transfection with DLS lipoplexes  
 Although DLS lipoplexes have been successfully applied for intracellular delivery of single 
strained oligonucleotides, cationic formulations can be toxic to cells, depending on the cell type. 
To evaluate whether DLS lipoplexes were toxic to N9 cells, cell viability was assessed following 
transfection by the Alamar Blue assay. As illustrated in Fig.25, when N9 cells incubated with DLS 
lipoplexes at a final concentration of 100 nM (the highest oligonucleotide concentration 
employed), a decrease in cell viability of nearly 30% was observed, both in anti-miR-21 and 
scramble transfected cells. The cytotoxicity mediated by DLS lipoplexes was found to be dose-
dependent, a decrease being observed with decreasing of the final oligonucleotide 
concentration (Fig. 25). These results may help to explain the unspecific decrease in miR-21 
expression levels observed following transfection with the scramble oligonucleotide (Fig.24). 
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 24 – Quantification of miR-21 in cells transfected with DLS 
lipoplex. N9 cells were transfected, 24 h after plating, with DLS 
liposomes complexed with FAM-labeled anti-miR-21 
oligonucleotides or scramble oligonucleotides, at an 
oligonucleotide concentration of 100 nM. Twenty-four hours after 
transfection, the cells were stimulated with 1 µg/mL LPS. Total 
RNA was then extracted and miR-21 levels were assessed in 
transfected and non-transfected cells by qPCR. Results are 
representative of three independent experiments. *** - P < 0.001. 
Fig. 25 – Assessment of cell viability. Twenty-four hours after plating, N9 cells were transfected with DLS lipoplex at 
an oligonucleotide final concentration of 25, 50 or 100 nM. Twenty-four hours after transfection, N9 cell viability 
was assessed using the Alamar Blue viability assay.  Results are representative of two independent experiments 
performed in triplicate. *** – P < 0.001. 
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4.2.6 – Microglia-mediated immune response upon miR-21 silencing via DLS lipoplex 
 
 Following the observation of a complete miR-21 silencing mediated by DLS lipoplexes in 
N9 cells, we further assessed how this miRNA could be important for microglia-mediated 
immune response. As shown in Fig.26 miR-21 silencing resulted in a reduction of NO production 
in LPS-incubated N9 transfected cells, which was dependent on the anti-miR-21 oligonucleotide 
final concentration (Fig.26a). However, we were not able to observe significant differences 
between anti-miR-21 and scramble conditions, probably due to unspecific effects of the 
scramble sequence (Fig.24). Taking into account that no significant decrease was detected in the 
viability of cells transfected with scramble oligonucleotide at final concentrations of 25 and 50 
nM, the unspecific effects associated with the scramble oligonucleotide are, most likely, a result 
of an unspecific interaction of the scramble oligonucleotide with miR-21 and not a result of the 
transfection process. 
 Concerning the mRNA levels of the two major cytokines IL-6 and IL-1β, we were able to 
observe significant differences in the IL-6 mRNA levels in cells transfected with anti-miR-21 
oligonucleotide and scramble oligonucleotide, at an oligonucleotide final concentration of 100 
nM. However, no significant differences in the IL-6 mRNA levels were detected when the cells 
were activated with LPS (Fig.26b). With respect to IL-1β mRNA no differences in the mRNA levels 
of this cytokine were observed, neither in the resting state, nor in an LPS-induced activated state 
(Fig.26c). 
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Fig. 26 – Assessment of microglia-mediated imune response following  miR-21 silencing via DLS lipoplex. (a) –  
Twenty-four hours after plating, N9 cells were transfected with DLS lipoplexes at oligonucleotide final 
concentrations of 25, 50 or 100 nM. Twenty-four hours after transfection, cells were incubated for 24h in the 
absence or presence of 1 µg/mL of LPS. Nitric oxide levels were assessed using the Griess test and the NO 
concentrations obtained were normalized with the total protein levels of each sample; (b) and (c) – IL-6 (b) and  IL-
1β (c) mRNA levels were determined in both resting and activated conditions by  q-PCR. Q-PCR results are presented 
as mRNA fold change  with respect to resting N9 untransfected cells; Results are representative of four independent 
experiments. ns – non-significant, * – P < 0.05, **  – P < 0.01, *** – P < 0.001. 
C
on
tr
ol
Sc
ra
m
bl
e 
25
 n
M
Sc
ra
m
bl
e 
50
 n
M
Sc
ra
m
bl
e 
10
0 
nM
A
nt
i-m
iR
-2
1 
25
 n
M
A
nt
i-m
iR
-2
1 
50
nM
A
nt
i-m
iR
-2
1 
10
0 
nM
C
on
tr
ol
Sc
ra
m
bl
e 
25
 n
M
Sc
ra
m
bl
e 
50
 n
M
Sc
ra
m
bl
e 
10
0 
nM
A
nt
i-m
iR
-2
1 
25
 n
M
A
nt
i-m
iR
-2
1 
50
nM
A
nt
i-m
iR
-2
1 
10
0 
nM
0
1
2
3
4
5
6
+ LPS 1 g/mL
***
***
[N
O
] 
( 
M
)/
m
g
/m
L
 p
ro
te
in
b 
a 
c 
C
on
tr
ol
S
cr
am
bl
e 
10
0 
nM
A
nt
i-m
iR
-2
1 
10
0 
nM
C
on
tr
ol
S
cr
am
bl
e 
10
0 
nM
A
nt
i-m
iR
-2
1 
10
0 
nM
0
1
2
5000
10000
15000
+ LPS 1g/mL
**
**
IL
-6
 m
R
N
A
 l
e
v
e
ls
 (
fo
ld
 c
h
a
n
g
e
)
Carlos Custódia 
 
57 
 
4.3 – MiR-21 silencing in microglia promotes glioma cell death 
 With the aim of understanding how miR-21 silencing in N9 microglia cells could affect 
their response to the glioma cells, we incubated GL261 cells (a mouse glioma cell line) with 
conditioned medium derived from either resting or LPS-activated wild type, GFP and 21 N9 cells, 
for 48h. We then assessed the extent of GL261 cell death, through flow cytometry analysis using 
Annexin-V-PE and 7-aminoactinomycin D (7-AAD) labeling, and caspase 3/7 activation using a 
fluorescence assay. Annexin-V specifically binds to phosphatidylserine (PS) residues, which are 
translocated from the inner leaflet to the outer leaflet of the cell membrane during apoptosis, 
thus effectively labeling apoptotic cells. On the other hand, 7-AAD is a fluorescent chemical 
compound which intercalates with DNA. This compound is only able to reach the DNA when 
membrane integrity is compromised, thus constituting a good indicator of necrosis. Double 
labeled cells (both Annexin-V and 7-AAD positive cells) are considered as late-apoptotic.  
As observed in Fig.27, exposure of GL261 cells to conditioned medium derived from LPS-
stimulated N9 21 cells resulted in an overall increase of cell death (particularly in the late 
apoptosis; Fig.27a), and in a significant increase in caspase 3/7 activation (Fig.27b). Interestingly, 
the conditioned media derived from wild type and GFP N9 cells seem to increase cell viability 
with respect to that observed in control conditions. Furthermore, these same conditioned 
mediums do not significantly induce caspase 3/7 activation. Therefore, taken together, these 
results suggest that miR-21 silencing in microglia sensitizes these immune cells towards a more 
effective immune response to glioma cancer cells. 
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Fig. 27 – Assessment of the extent of glioma cell death after incubation with microglia conditioned medium. 
GL261 cells were plated 24h before incubation with microglia conditioned medium derived from either resting (non-
activated-CM) or wild type, GFP and 21 N9 cells stimulated with 1 µg/mL of LPS (activated-CM). a – After incubation, 
cells were labeled with Annexin-V-PE and 7-AAD and analyzed by flow cytometry; 10.000 events were collected per 
sample. As a positive control, cells were incubated with 10 µM of Vinorelbine.; b – After incubation with the 
conditioned media, cells were collected and lysed and caspase 3/7 substrate was then added to the supernatant. 
Caspase 3/7 activity was analysed by fluorescence spectroscopy and results are presented as fold change with 
respect to control (untreated cells). Results are representative of three independent experiments. ns – non-
significant; *  – P < 0.05; ***  – P < 0.001. 
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 Over the past few years the interest in understanding microglia-mediated immune 
response to glioma tumors has increased, and the ability of glioma cells to modulate microglia-
mediated immune response has been a matter for debate. Clinical observations and in vitro 
studies indicate that microglia and macrophages can infiltrate the brain tumor tissue in high 
numbers and may play a supportive role during tumor development through the expression of 
matrix metalloproteinases that lead to tumor growth and infiltration [64]. Several studies also 
suggest that the glioma microenvironment can modulate the phenotype of infiltrating microglia 
and macrophages, causing an impairment or complete ablation of pro-inflammatory cytokine 
production [48, 49, 67].  
 In the present study, we observed that glioma conditioned medium derived from GL261 
cells (mouse glioma cell line) induced a significant expression of two pro-inflammatory cytokines 
IL-1β and TNF-α (Fig.14a and b) and a slight decrease of SOCS-1 (inhibitor of cytokine signaling), 
suggesting that microglia activation is not completely impaired in these cells. A slight increase in 
the levels of miR-155 (Fig. 16b), which is known for being a pro-inflammatory miRNA, as well as 
a significant increase in the mRNA levels of iNOS, an enzyme responsible for the production of 
NO and a potent pro-inflammatory mediator. Interestingly, despite the significant enhancement 
of iNOS mRNA levels by glioma conditioned medium, no NO production was detected. However, 
when the cells, previously exposed to glioma conditioned medium, were incubated with LPS, NO 
production was significantly higher with respect to NO production in cells incubated with LPS 
alone. Under these conditions, an increase in the mRNA levels of iNOS was also observed 
(Fig.15). Finally, a significant increase in the levels of miR-21 was detected, a miRNA reported as 
being involved in the regulation of immune response [83], although the role of this miRNA in 
such process remains unclear. Inthis regard, contradictory data have been reported in the 
literature in the literature, suggesting either a pro [130] or an anti-inflammatory [106] role for 
this miRNA. 
Our results are in agreement with those obtained by Kees and colleagues, which 
revealed that microglia isolated from gliomas supported tumor cell growth, migration, and 
invasion [131]. However, the authors have shown that upon stimulation of tumor isolated 
microglia with poly (I:C) (a TLR-3 agonist), microglia secreted factors that exerted toxic and 
suppressive effects on glioma cell lines. Another study performed by Yeh and colleagues 
reported that glioma cells stimulate microglia to produce pro-inflammatory cytokines, which are 
then used by glioma cells to enhance their migration ability [132]. 
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Taken together, our results suggest that microglia does not respond strongly to glioma-
conditioned medium. However, when microglia cells are stimulated with stronger activation 
stimuli, such as LPS, followed by incubation with glioma conditioned medium, an enhancement 
in the immune response is observed. These findings suggest that under these conditions, 
microglia is induced to a “primed state” in its immune response and both miR-155 and miR-21 
may play a role in this priming process. 
The results presented in Fig. 16 show that miR-21 and miR-155 were overexpressed in 
N9 microglia cells following incubation with glioma conditioned medium derived from GL261 
cells. Since miR-155 has already been described by us and others as being a pro-inflammatory 
miRNA, responsible for the regulation of microglia mediated immune response through SOCS-1 
targeting [120, 121], attention on miR-21 was focused and how the silencing of this miRNA could 
affect microglia immune response. 
In order to answer this question we silenced miR-21 in N9 microglia cells using two 
different strategies: lentiviral transduction and DLS lipoplex transfection. Our results have shown 
that miR-21 silencing in microglia strongly affected its ability to produce NO upon LPS 
stimulation and significantly decreased the levels of the pro-inflammatory cytokine IL-6 when 
the cells were in the resting state (Fig. 19a and b). On the other hand, IL-1β levels were not 
significantly affected by miR-21 silencing (Fig.19c). Our results corroborate the work performed 
by Weber and colleagues, in which the authors reported that miR-21 expression is directly 
proportional to NO production. In their study, performed in endothelial cells, the authors 
observed that miR-21 silencing reduced eNOS phosphorylation and NO production, while miR-21 
overexpression increased both eNOS phosphorylation and NO production [133]. Since PTEN has 
been reported has being a direct target of miR-21 and shown to negatively regulate eNOS 
phosphorylation and NO production, through the antagonism of the PI3K/Akt pathway [134], a 
link can be proposed between miR-21, PTEN expression and NO production, where miR-21 
overexpression suppresses PTEN expression and increases both Akt and eNOS phosphorylation, 
resulting in an increase of NO production [133].  
In another recent study performed by Okayama et al. it was reported that miR-21 
induction is dependent on iNOS through KRASG12D activation [135]. KRASG12D is a mutated form of 
the GTPase Ras protein which has been associated to enhance cell proliferation and 
tumorigenesis [136]. The authors based their assumptions on another previous study where it 
was described that Ras activation increases the expression of miR-21, and in turn, miR-21 
enhances tumor proliferation and survival by targeting both antagonists of Ras signaling 
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pathways and proapoptotic genes [137]. In their own study, Okayama and colleagues, silenced 
iNOS in KRASG12D transgenic mice and investigated miR-21 expression in both iNOS wild type and 
iNOS silenced KRASG12D transgenic mice. They observed that iNOS deficiency alone did not alter 
miR-21 expression without KRAS activation, but significantly reduced miR-21 expression when 
KRAS was activated. From these results they suggest that iNOS may alter miR-21 expression 
depending on the activation of KRAS. Given that miR-21 is a downstream target of Ras, the 
authors propose a regulation of miR-21 expression by iNOS-derived NO [135]. Although we did 
not check iNOS levels in microglia cells with silenced miR-21, taken together with the results 
reported by Weber and by Okayama, our data suggest that iNOS levels and miR-21 expression 
are mutually dependent, and a regulatory feedback loop may exist involving iNOS, KRAS and 
miR-21, which will affect NO production. 
 Regarding PDCD4, IL-6 and miR-21, in a study performed by Sheedy et al., it is suggested 
that PDCD4, is required for IL-6 expression [106]. Our results, have shown that lentiviral 
mediated miR-21 silencing in N9 microglia cells (N9 21 cells) led to an increase in PDCD4 mRNA 
and protein levels when the cells were in a resting state (Fig.20). However, contrary to the 
results of Sheedy and colleagues, miR-21 silencing resulted in a significantly decrease in the 
levels of this cytokine with respect to lentiviral-transduced control cells (N9 GFP cells; Fig.19b). 
Moreover, when both cell lines (N9 21 and N9 GFP) were stimulated with LPS, PDCD4 mRNA 
levels were significantly higher in N9 21 cells as compared to N9 GFP cells (Fig.20). On the other 
hand, no significant differences could be observed in IL-6 levels between the two types of cells, 
although a small decrease in the amount of IL-6 could be detected in N9 21 activated cells. 
Furthermore, following DLS lipoplex-mediated miR-21 silencing, an even larger difference was 
observed in the IL-6 levels of resting N9 cells transfected with anti-miR-21 oligonucleotides with 
respect to both scramble-transfected and untransfected cells (Fig.26). However, we were not 
able to observe the same tendency as that detected in the lentiviral transduced cells, when the 
cells were stimulated with LPS following DLS-mediated miR-21 silencing, probably due to the fact 
that the scramble oligonucleotide interacts inespecificaly with miR-21 (as shown in Fig.24). 
Overall, our results indicate that IL-6 expression is partially dependent on miR-21 levels, but in a 
PDCD4 independent manner. In addition, other studies have suggested that miR-21 is induced by 
IL-6 overexpression in a STAT-3 dependent way [125, 138]. Taken into consideration all these 
findings we suggest that miR-21 and IL-6 levels are possibly dependent from each other through 
a mechanism that, although not completely clear, seems to be independent of PDCD4 
expression. 
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 As previously discussed, glioma cells induce a slight immune response in microglia, 
increasing the levels of the cytokines IL-1β and TNF-α, significantly inducing the expression of 
iNOS mRNA, and inducing the expression of both miR-21 and miR-155. Surprisingly, an increase 
in glioma cell viability was observed, when glioma cells were exposed to conditioned medium 
derived from resting or LPS-activated wild type, GFP or 21 N9 microglia cells, with respect to 
control cells (untreated cells) (Fig.27a). These results indicate that this immune response is not 
efficient in promoting tumor cell death, which is in agreement with the results obtained by other 
groups [64, 66]. Interestingly, the only exception observed to this tendency regards the cells 
exposed to conditioned medium derived from LPS-activated N9 21 cells. Under these conditions, 
we observed an increase in late apoptotic cells with respect to control cells (Fig.27a). Moreover, 
when (Fig.27b) glioma cells were incubated with conditioned media derived from wild type and 
GFP N9 cells no significant change in the activity of caspase 3/7 was obtained. However, the 
medium derived from activated N9 21 cells, significantly induced caspase 3/7 activity in glioma 
cells. Taken together, these results suggest that miR-21 silencing in microglia may affect the 
ability of these cells to respond to glioma cells.  
 In a study performed by Frei and colleagues, it was reported that FasL, a ligand of FasR 
(also known as CD95/APO-1) which is a cell surface receptor and member of the tumor necrosis 
factor receptor superfamily implicated in apoptosis, was able to induce apoptosis in several 
glioma tumor cell cultures isolated from human patients [139]. Another study performed by 
Rubinchik et al., showed that FasL, in combination with TNF-related apoptosis-inducing ligand 
(TRAIL), enhanced apoptosis in glioma cell lines [140]. Interestingly, FasL has been reported as a 
direct target of miR-21 [141], and, therefore, an enhanced expression of FasL in N9 21 cells 
might be a plausible explanation for the results observed in glioma cell viability and caspase 3/7 
induction after incubation with the conditioned medium derived from N9 21 activated cells. 
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6 – Concluding remarks and future perspectives 
 
 The results obtained in this work led to several interesting conclusions.  
 Glioma-conditioned medium leads to priming of microglia-mediated immune response 
From the results observed when microglia is exposed to conditioned medium derived 
from glioma cells, we can suggest that microglia does not strongly respond to glioma cells. 
However, an enhancement in microglia-mediated immune response was observed when 
microglia cells, previously exposed to glioma conditioned medium,are submitted to a strong 
stimulus. These findings suggest that microglia might be primed by glioma cells to strongly 
respond to a pro-inflammatory stimulus. Moreover, the induction of miR-21 and miR-155 
expression in microglia cells following exposure to glioma conditioned medium suggests that 
both these miRNA may play a role in this priming process. 
 Silencing of miR-21 affects microglia-mediated innate immune response 
 From the results observed on the decreased NO production and expression of IL-6 in 
resting microglia cells, previously transduced/transfected to silence miR-21, we can suggest that 
miR-21 plays an important role in microglia-mediated immune response. Although these effects 
were abolished when cells were stimulated with LPS, a tendency towards a lower expression of 
IL-6 with respect to control cells was observed. However, miR-21 silencing did not seem to 
influence the expression of IL-1β, TNF-α or IFN-β (data not shown), indicating that these 
particular inflammatory mediators are not under the influence of this miRNA. 
 MiR-21 silencing in microglia increases cell glioma cell death 
 From the results obtained on the increase of glioma cell death and caspase 3/7 
activation upon incubation with microglia-derived conditioned medium, we can suggest that 
miR-21 is important during microglia-mediated response to glioma tumor cells. It would be 
interesting to evaluate a possible role of FasL signaling in this process, since this ligand has been 
reported not only to enhance glioma cell apoptosis, but also to be a direct target of miR-21.  
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